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ABSTRACT
In this dissertation physicochemical properties of the 
Bs vitamer, pyridoxal hydrochloride (PL HC1), are 
investigated with the aim of generating the necessary 
profile for the rational development of a stable, safe 
and effective formulation containing this drug. Recent 
research suggests that administration of PL HC1 may be 
particularly effective in raising the depleted 
intracellular pyridoxal phosphate levels found in many 
asthmatics treated with theophylline. The solubility 
characteristics of PL HC1 suggest that its absorption 
and bioavailability should not be problematic. An 
investigation of the solid state properties of PL HC1, 
using thermal analysis combined with infra-red
spectrophotometry indicated the existence of at least 
two polymorphs. Subseguent studies demonstrated that 
polymorphic transformations may also be induced at 
moisture levels of 57-68% relative humidity. The 
moisture sorption isotherm derived for PL HC1 by Karl 
Fischer titration also provided evidence of two 
polymorphs of markedly different hygroscopicity.
Atmospheric moisture was also shown to be a highly 
significant destabilizing factor with respect to 
chemical stability. In a further study a Plackett-Burman 
factorial design was used to investigate PL-excipient 
compatibility. Colloidal silicone dioxide, celluloses 
and magnesium stearate were found to have significant 
stabilizing effects, whilst lactose, starch and mannitol
11
were found to be incompatible. These results were also 
confirmed by a study employing differential scanning 
calorimetry and conventional "one factor at a time" 
isothermal stress testing. Many of the formulation 
problems posed by PL HCl can be related to the 
hemiacetal group and its corresponding aldehyde. These 
make PL HCl an inherently unstable and reactive drug 
molecule. A further contributing factor is the 
hygroscopicity of the compound. Taking the above 
findings into consideration, with careful selection of 
formulation components, manufacturing procedures and 
storage conditions, a stable and effective drug delivery 
system containing PL HCl can be envisaged.
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CHAPTER ONE
1 INTRODUCTION
Preformulation research encompasses the pharmaceutical 
and analytical investigations which precede and support 
the development and design of new dosage forms. 
Preformulation can thus be regarded as the first 
learning phase about a new drug candidate which has been 
selected (on the basis of pharmacological and 
toxicological studies), for development into a 
marketable pharmaceutical product. Such products should 
be stable, possess good bioavailability and be patient 
acceptable. The principle activity during this 
developmental phase is the generation of a detailed 
profile of pharmaceutically relevant and useful 
physicochemical properties of the drug substance and its 
combination with other bioactive substances, selected 
solvents, excipients and packaging components (Motola 
and Agharkar, 1984).
There is no definitive approach to preformulation. A 
number of reviews outlining various preformulation 
methodologies and interpretations have been published 
(Wells, 1989a; Motola and Agharkar, 1984; Fiese and
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Hagen, 1986; Nyqvist, 1986; Boatman and Johnson, 1981). 
However, certain fundamental aspects are common to all 
preformulation studies. Preformulation studies are 
undertaken during the early stages of product 
development and often only small quantities of bulk drug 
(milligrams rather than grams) are available for 
experimentation (Wells, 1989b). Furthermore, due to the 
competitive nature of the pharmaceutical industry and 
the high costs involved in research, time is also 
limited. Crucial data must therefore be generated within 
months in order to (a) highlight the need for further 
modification to the drug substance (eg. salt formation 
or crystal modifications) to eliminate undesirable 
physicochemical properties and (b) to rapidly facilitate 
progress toward clinical studies. It is for this reason 
that the determination of the intrinsic solubility and 
pka are mandatory for any new compound (Wells, 1989b). 
These fundamental properties immediately indicate the 
need and possibility of making more soluble salts of the 
drug to eliminate solubility related bioavailability 
problems.
The dual restrictions of limited time and initial drug 
quantity make it essential that investigators be 
pragmatic and only generate data which is of immediate 
relevance (eg. detailed mechanistic and kinetic studies 
should be reserved for later stages of the development 
program). In addition, experiments must always be 
designed to obtain maximum useful information with
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limited bulk. To achieve this, interrelationships 
between various physicochemical properties can be made 
use of. By determining a number of fundamental 
physicochemical properties a number of others can be 
derived (Wells, 1989b). Various physicochemical 
properties which are commonly examined in preformulation 
and their interrelationships are shown in figure 1.1.
DRUG CANDIDATE
IJ'CHROMOPHORE-*— STRUCTURE---- ~ l2'o values ---- - ’ pK ,-- —(J,log P -----— 1 ACTIVITY♦|
BIOAVAILABILITY
1J*'UV ANALYSIS ‘' STABILITY-*- 4 HYGH0SC0PICITY-,J‘SALTS- J,S0LU 8ILITY-‘J,0 ISS0LUTI0N
“ HPLCTLC____ '’ EXCIPIENT „
1 COMPATIBILITY - ’ MELTING POINT '’ ‘ ‘SOLVENTS
’ PROCESSING** ^ CRYSTALLOGRAPHY — ’’ ’POLYMORPHISM
“ SOLUBILITY PARAMETERS
Figure 1.1 The interrelationship of drug properties 
examined in preformulation
Furthermore, wherever possible theory and prediction 
should be applied to reduce experimentation or to 
channel experimentation into more specific directions. 
It is also often possible to limit experimentation by 
making use of existing data on the compound. Sources 
include reports from the organic research chemists 
involved in the synthesis of new substances and reports 
on pharmacological, toxicological and biochemical 
studies on the new compound. Useful data may also be 
obtained from literature describing analogues of the 
compound which may already be in use.
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In preformulation each drug candidate must therefore be 
considered individually and the amount of pre-existing 
data and the types of dosage forms likely to be employed 
must be taken into account before the scope and design 
of the preformulation program is decided upon.
In this dissertation a preformulation study of pyridoxal 
hydrochloride is presented. Pyridoxal hydrochloride (PL 
HC1) is the hydrochloride salt of pyridoxal (PL), one of 
six Bs vitamers found in nature (Figure 1.2).
Ri r 2
c h 2oh H Pyridoxine(PN)
c h 2oh PO,2' Pyridoxine-5-phosphate(PNP)
c h 2n h 2 H Pyridoxamine(PM)
c h 2n h 2 PCV~ Pyridoxamine-5-phosphate(PMP)
CHO H Pyridoxal(PL)
CHO PO,2’ Pyridoxal-5-phosphate(PLP)
Figure 1.2 The six B6 vitamers
The term vitamin Bfi refers to all 3-hydroxy-2-methyl 
pyridine derivatives which mimic the biological activity 
of pyridoxine (PN). However pyridoxal-5-phosphate (PLP) 
is the only active coenzyme form of vitamin B6. The other 
vitamers therefore undergo biotransformation to PLP in 
order to exert their biological effect.
PLP participates in at least 100 different enzymatic
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reactions (Sauberlich, 1985). PLP is an essential 
coenzyme in amino acid metabolism and participates in 
the deamination, decarboxylation, transamination, 
racemization and transsulphuration of amino acids. In 
brain metabolism PLP acts as the codecarboxylase to 
specific amino acid decarboxylases involved in the 
production of neurogenic amines and neurotransmitters 
(eg. serotonin, dopamine and noradrenaline) from amino 
acids such as tryptophan, tyrosine and phenylalanine 
(Table 1.1) (Marks, 1975).
Table 1.1 Biologically important amines derived from 
amino acids or amino acid derivatives under action of 
decarboxylase and PLP
Amino Acid Amine
Histidine Histamine
5-Hydroxytryptophan 5-Hydroxytryptamine(serotonin)
Aspartic acid p-Alanine
Glutamic acid g-aminobutyric acid (GABA)
Phenylalanine Noradrenaline
Tyrosine Adrenaline
Tyramine
Dopamine
Cysteic acid Taurine
Further biochemical processes which require the presence 
of PLP include the biosynthesis of coenzyme A, the 
conversion of linoleic acid to arachidonic acid in the 
metabolism of essential fatty acids, the incorporation 
of iron during haemoglobin synthesis and porphyrin 
biosynthesis (Marks, 1975; Ebadi, 1986).
Furthermore PLP takes part in the metabolism of a number 
of other vitamins. Vitamin Bs deficiency results in
5
andreduced absorption and storage of vitamin B12 
increased vitamin C excretion. Through its involvement 
in tryptophan and kynurenine metabolism, PLP is also 
involved in nicotinic acid (vitamin B3) biosynthesis 
which is disrupted in vitamin B6 deficiency (Marks, 1975; 
Ebadi, 1986).
Due to its important physiological functions and its 
widespread involvement in metabolism throughout the 
body, vitamin Be has also been implicated in the 
aetiology and therapy of a number of disease states and 
physiological conditions. The therapeutic use and 
pharmacology of vitamin Bs has been comprehensively 
reviewed by a number of authors (Reynolds and Leklem, 
1985; Lui and Lumeng, 1986). This topic is only briefly 
discussed here with emphasis on some of the more recent 
findings concerning the therapeutic use of vitamin Bs. 
Apart from nutritionally induced vitamin B6 deficiency, 
reports of the successful treatment of a whole range of 
seemingly unrelated diseases with vitamin B6 are 
available. These include asthma (Reynolds and Natta, 
1985), liver disease (Lui and Lumeng, 1986), autistic 
syndrome (Rimland et al. 1978), premenstrual tension
(William et al. 1985) and gestational diabetes (Bennik 
and Scheurs, 1975). Furthermore, a series of genetic 
diseases which do not cause vitamin Bs deficiency, but 
which respond to Bs therapy is known. These include 
homocystinuria, gyrate atrophy of the choroid and 
retina, hereditary sideroblastic anaemia, infantile
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convulsion, primary cystathioninuria, xanthuremic 
aciduria and primary hyperoxaluria (Lui and Lumeng, 
1986). Vitamin Bs deficiency has also been found to be 
prevalent in pregnancy and lactation. Finally, vitamin 
B6 deficiency can also be acquired from the use of 
certain drugs. Increased vitamin Bs requirements are 
frequently found in alcoholics and women using oral 
contraceptive agents. Other drugs known to interact with 
vitamin Bfi are isoniazid, cycloserine, penicillamine, 
hydralazine and levodopa. In the case of levodopa, 
vitamin B6 acts as an antagonist, completely anulling the 
beneficial effects of levodopa in Parkinsons disease. 
However, serious vitamin Bs deficiency does not usually 
occur and vitamin Bs is therefore contra-indicated in 
levodopa therapy (Lui and Lumeng, 1986).
More recently, signs of vitamin Bs deficiency first 
observed in some asthmatics by Collip and co-workers 
(1973) and later by Reynolds and Matta (1985), have been 
observed and reported by Delport et al (1988). These 
workers demonstrated significantly decreased plasma PLP 
levels in asthmatics. In their study they also observed 
that 82% of patients regularly received theophylline 
therapy. Administration of theophylline to a group of 
17 volunteers also resulted in large reductions in 
plasma PLP, however plasma PL was not affected. In a 
placebo controlled, double blind follow up study 
theophylline induced depressed plasma PLP levels were 
again demonstrated. It was also shown that theophylline
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is a potent non-competitive inhibitor of PL kinase (EC 
2.7.1.35).
PL kinase is a key enzyme in vitamin B6 metabolism and is 
widely distributed in mammalian tissues (McCormick 
al. 1961). Extracellular (plasma) PL is the major source 
of PLP (the active coenzyme) for extrahepatic tissues. 
Extracellular PL is transported across the plasma 
membrane and subsequently phosphorylated by pyridoxal 
kinase (Figure 1.3) (Mehanso and Henderson, 1980; 
Anderson et al. 1971; McCormick et al. 1961). In
contrast, plasma PLP can not serve as a direct source of 
intracellular PLP as it is predominantly albumin bound 
and is more polar than PL. It therefore can not be 
transferred across plasma membranes (Anderson et al. 
1971; Lumeng and Li, 1980). Plasma PLP can thus only 
serve as a vitamin B6 source to extrahepatic tissues 
after dephosphorylation to PL. Although PN (the most 
commonly found form of vitamin B6) can cross plasma 
membranes and can be phosphorylated by PL kinase, it too 
can not act as a direct source of intracellular PLP as 
conversion of PNP to PLP requires pyridoxine-5-phosphate 
oxidase enzyme which is absent in most extrahepatic 
cells (Lumeng et al. 1985). Most extrahepatic tissues 
are therefore dependent on adequate levels of plasma 
pyridoxal and pyridoxal kinase activity to ensure 
adequate intracellular PLP levels.
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Biotransformation 
in liver
(eg smooth muscle)
Figure 1.3 Pathway for conversion and transport of 
vitamin B6 compounds in plasma after pyridoxine (PN) 
ingestion. * Denotes points where theophylline inhibits 
vitamin B6 metabolism. Key: PL-pyridoxal; PM-pyridoxamine 
PNP, PLP, PMP-phosphorylated derivatives of PN, PL and 
PM respectively; 4PA-4 pyridoxic acid; RBC red blood 
cell;
Due to the widespread involvement of PLP in human 
metabolism, theophylline induced inhibition of PL kinase 
could have serious and far reaching consequences for 
asthmatics receiving theophylline treatment. Ubbink g£ 
al (1989) have shown that after short term theophylline 
treatment, the deranged PLP metabolism can be restored 
to normality by vitamin Bs supplementation (10 mg PN 
daily). In previous studies clinical improvement in 
asthmatic patients was also observed after vitamin B6 
supplementation (Reynolds and Natta, 1985; Collip et al. 
1975).
It is therefore apparent that vitamin Bs supplementation 
may be of considerable value in asthmatics receiving
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theophylline therapy. Furthermore the use of pyridoxal 
rather than pyridoxine should be considered. Currently 
PN HC1 is the only form of vitamin Bs approved for 
clinical use. This can be attributed to the superior 
stability profile of PN HC1 when compared to the other 
B6 vitamers and the lack of evidence supporting the need 
for any other Bs compound in clinical practice (Lumeng, 
1986). However as it is now clear that adequate 
intracellular PLP is dependant on adequate circulating 
PL levels, it is obvious that administration of PL is 
advantageous as this would be directly available to the 
circulation and the extrahepatic tissues. PL could thus 
rapidly counteract the imbalance in intracellular PLP 
which may be present in theophylline treated asthmatics 
and which may also prevail in many other vitamin B6 
dependent conditions. On the other hand, as previously 
outlined, PN can not be directly converted to PLP by 
extrahepatic tissues. Utilisation of PN thus depends on 
adequate vitamin B6 metabolism in the liver (Figure 1.3). 
This is particularly problematic in patients receiving 
theophylline therapy as phosphorylation of PN by PL 
kinase is one of the critical steps in this process. As 
theophylline is now known to inhibit PL kinase it can 
therefore also be expected that hepatic conversion of PN 
to PL is not as efficient as in normal patients. This 
would result in a lower circulating PLP pool and 
ultimately lower levels of extracellular PL. Finally, 
although PL has been clearly shown to be more unstable 
than PN, this should not be viewed as an insurmountable
10
obstacle as with modern formulation technology, accurate 
analytical instruments and a better understanding of
incompatibility and stability programs many unstable 
drugs can be stabilised and incorporated in specific 
drug formulations.
As a first step in the development of a solid dosage 
form containing pyridoxal, possibly in combination with 
theophylline or other multivitamins, a preformulation 
study of PL HC1 was undertaken. For economic and
practical reasons the hydrochloride salt of PL was
selected as this is currently the only commercially 
available form of PL. It was therefore decided that
synthesis and use of other salts of PL would only be 
considered if the physicochemical properties of PL HC1 
were found to be totally unsuitable for the purposes of 
producing a stable, solid dosage form.
The aim of this preformulation study is to generate the 
necessary physicochemical data to enable the rational 
formulation design of stable, safe and effective solid 
dosage forms containing PL HC1. In order to achieve
this the study was subdivided into the following four 
sections:
(1) analytical preformulation,
(2) elucidation of the solid state properties 
of PL HC1,
(3) solubility analysis of PL HC1 and
(4) stability analysis of PL HC1.
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CHAPTER TWO
2 METHODS FOR THE ANALYSIS OF PYRIDOXAL HCL
2.1 INTRODUCTION
The first task that the preformulation scientist faces 
is the development of suitable analytical methods. In 
this process use must be made of any relevant 
information which may have accumulated during the 
synthesis and basic chemical research on the compound. 
A literature search for references to the compound or to 
better known analogues must also be conducted. As both 
material and time is usually limited during this stage, 
the methods should be relatively simple, thus not 
requiring lengthy development. Naturally the analytical 
methods should also be sensitive thus only requiring 
small samples. Analytical preformulation can be seen 
to serve two purposes: The immediate and obvious purpose 
is the development of methods that enable the 
elucidation of pharmaceutically relevant physicochemical 
properties. Secondly, the methods developed and the 
information gathered in the process may form the basis 
for analytical methods used in later, more detailed 
formulation studies and for quality control of the final 
dosage form. Valuable analytical methods routinely used
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in preformulation studies include ultra violet (UV) 
spectroscopy, thin layer chromatography (TLC), high 
performance liquid chromatography (HPLC) and thermal 
analysis. Others include infra-red (IR) spectroscopy, x- 
ray diffraction techniques, Karl Fischer titration and 
other titrimetric techniques.
Establishing a UV spectrophotometric method is often the 
first step in preformulation. For most drugs UV 
spectroscopy can be used to make sensitive, quantitative 
determinations of the pure drug in solution 
(Wells, 1988c). This method can then be applied to the 
study of vital solubility characteristics such as 
intrinsic solubility, pH solubility profiles, pks values 
and partition coefficients.
TLC is frequently used as a semi-quantitative stability 
indicating method. It is generally regarded as a simple 
and reliable method for separating drug from impurities, 
degradation products and excipients. TLC therefore 
frequently finds application in the initial solid state 
stability analysis and in excipient compatibility 
studies. TLC is especially useful in excipient 
compatibility studies , where numerous drug-excipient 
combinations have to be tested. With TLC up to 15 
samples can be analysed simultaneously allowing 
considerable savings of time and solvents when compared 
to HPLC.
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HPLC is currently acknowledged as the most versatile and 
powerful technique in pharmaceutical analysis and is the 
method of choice for stability studies (Wells, 1988d). 
HPLC has advantages over traditional techniques such as 
spectrophotometry, titrimetry and TLC in that it is both 
highly specific and quantitative. Furthermore the 
technique lends itself well to automation. The 
disadvantages are the relatively high hardware costs as 
well as the high running and maintenance costs (columns, 
solvents and other disposables). In the absence of 
automation HPLC can also be very time consuming 
(Boehlert, 1984). HPLC should therefore be reserved for 
applications where simpler quantitative techniques such 
as UV spectroscopy are not specific enough, or where the 
semi-quantitative approach offered by TLC is inadequate.
Also valuable in preformulation are the thermal 
analytical techniques. Various thermal techniques are 
available. These include differential scanning 
calorimetry (DSC), thermal gravimetric analysis (TGA) 
and hot stage microscopy (HSM). Other thermal
techniques, less frequently used in preformulation 
studies include thermomechanical analysis and evolved 
gas detection. Thermal analysis is generally rapid and 
requires only a few mg of drug, yet techniques such as 
DSC, TGA and HSM can yield a wide range of qualitative 
data. DSC can be applied to accurately determine the 
purity of the drug candidate and can be used together 
with TGA and HSM to rapidly generate a physical profile
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of the drug substance (eg melting point, extent of 
crystallinity, the presence of amorphous forms, 
polymorphs and solvates). DSC is also increasingly used 
in drug excipient compatibility screening (Giron, 1986; 
Giron-Forest, 1984; Wollmann and Braun, 1983). Unlike 
traditional compatibility screening tests, no prolonged 
storage of samples under isothermal stress conditions is 
required. However, interpretation of the thermograms can 
be difficult and confirmation of stable drug-excipient 
mixtures is therefore usually obtained by isothermal 
stress testing and subsequent TLC or HPLC analysis (van 
Dooren, 1983).
Karl Fischer titration is an analytical method used for 
the determination of water. It is mentioned here as 
moisture content and moisture sorption are of central 
importance for both physical and chemical drug stability 
and no preformulation study can be completed without 
considering the effect that atmospheric moisture has on 
the drug. Moisture content and moisture sorption 
profiles are also frequently determined gravimetrically. 
However, gravimetric techniques do not account for 
residual organic solvents which may be displaced by 
adsorbed moisture (Nyqvist, 1986). Furthermore with 
modern automated equipment quantities of water as low as 
10 ug (Mettler instrumentation specifications) can be 
accurately and rapidly determined by Karl Fischer 
titration.
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The five above mentioned techniques were extensively 
used during the preformulation investigation of PL HCL. 
The development of assays using these techniques is 
described in detail in this chapter. Where necessary, 
assay validation was carried out using standard 
statistical procedures as described by Cavenaghi et al 
(1987). IR spectroscopy and scanning electron microscopy 
(SEM) were also used. However, these did not require any 
specialized method development and are therefore not 
discussed here.
2.2 UV SPECTROPHOTOMETRIC ANALYSIS OF PYRIDOXAL HCL
2.2.1 OVERVIEW OF EXISTING METHODS
In aqueous solution PL undergoes a number of ionic 
transitions with changing pH. Consequently UV light 
absorption and the spectral properties of PL are also 
highly pH dependant (Morosov, 1986) (see section 4.3.2). 
Any method for the spectrophotometric determination of 
PL must therefore specify the pH at which absorption 
measurements are made. At pH 2 the absorption maximum 
for PL in aqueous solution is 286 nm. This maximum can 
be conveniently used to quantitatively assay PL in 
solution (Strohecker and Henning, 1965). However, this 
simple method is only suitable for the determination of 
pure PL solutions with no UV absorbing impurities and is 
generally not suitable for the determination of PL in 
the presence of other vitamins and drugs. Better 
selectivity can be achieved by making use of reagents
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which react with specific functional groups on the PL 
molecule. The newly formed complex can then be measured 
spectrophotometrically. Two such methods are the method 
of Hochberg et al (19441 (reaction with dichloroquinone 
chlorimide) and the method of Hrdy and Urbanova (1957) 
(reaction with p-diethylaminoaniline).
These methods are sufficiently selective to allow the 
determination of pyridoxine (PN) in the presence of 
closely related PL . They have also been successfully 
used to determine PN in multivitamin preparations. These 
methods could be modified to enable the determination of 
PL rather than PN. However both methods have serious 
disadvantages. The method of Hochberg et al (1944) has 
poor colour stability and all measurements have to be 
made within 60-80 seconds (optimally 80 seconds) of 
reagent addition. The method of Hrdy and Urbanova (1957) 
on the other hand requires extraction of the PN complex 
into benzene before measurement.
An alternative method was therefore developed based on 
a procedure recently reported for PN determination 
(Nirmalchandar et al. 1987). The method utilizes the 
coupling reaction of 4-aminoantipyrine with phenolic 
type compounds in the presence of a strong oxidizing 
agent. This reaction has long been exploited for the 
spectrophotometric determination of phenolics in 
industrial effluent (Mohler and Jacob 1957). Similar 
assays have also been reported for phenylephrine and 
piroxicam (Parasrampuria and Das Gupta, 1990).
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2.2.2 METHODOLOGY
2.2.2.1 MATERIALS AND APPARATUS
The following analytical grade reagents were used: 
Pyridoxal HC1 (Fluka, Buchs), pyridoxine HC1 (BASF, 
Ludwigshafen), 4-aminoantipyrine (Fluka, Buchs),
ammonium persulfate (BDH, Poole), hydrochloric acid 
(BDH, Poole). Double distilled water (Mini Q System, 
Millipore, Bedford MA) was used throughout. The
following excipients were mixed with PL HC1 to simulate 
analytical samples: Avicel PH 101 (FMC
Corp,Philadeladelphia PA) f corn starch (Holpro,
Johannesburg), anhydrous lactose (Sheffield,Norwhich NY) 
and magnesium stearate B.P.. A Phillips/Pye Unicam 
(Cambridge) PU8700 UV/visible spectrophotometer with 1 
cm quartz cells was used for the absorbance
measurements.
2.2.2.2 PROCEDURE
A PL stock solution was prepared by dissolving 
approximately 10 mg of PL HC1 (accurately weighed) in 
100 ml of distilled water. A series of PL standards 
ranging between 10 and 3 0 mg/1 was prepared in 10 ml 
volumetric flasks by taking appropriate aliquots of 
stock solution, adding 1ml of a 0.4% aminoantipyrine and 
a 1% ammonium persulfate solution respectively and 
making up to volume with distilled water. This procedure 
was also used to prepare analytical samples consisting 
of pure PL in solution. Analytical samples consisting of
18
PL-excipient mixtures were added to 100 ml volumetric 
flasks, made up to volume with water and shaken for 10 
minutes. An aliquot of this solution (3 ml) was then 
passed through a 0.45 pm filter membrane (Millex HV, 
Millipore, Bedford MA). The procedure described for the 
preparation of standard solutions was then followed. All 
analytical sample solutions were adjusted to pH 2.5 with 
dilute hydrochloric acid. Standard and sample solutions 
were allowed to stand for 20 minutes after reagent 
addition. Absorbance was then measured at 408 nm against 
a reagent blank. The linearity, detection limit, 
precision and accuracy of the method were assessed. 
Selectivity was evaluated by the addition of various 
water soluble vitamins including pyridoxine. All 
solutions were prepared in red light and stored in 
closed bottles. The vitamin solutions were overlayed 
with nitrogen gas and stored in a refrigerator. Reagent 
solutions and the PL stock solution were prepared daily.
2.2.3 RESULTS AND DISCUSSION
The absorption spectrum has a broad maximum at 408 nm 
(Figure 2.1). In the pH range of 2.45-2.60 absorption 
was found to be constant, but time dependent. Maximum 
absorbance was reached 20 minutes after the reaction was 
initiated and remained constant for a further 15 minutes 
(Figures 2.2 and 2.3).
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Figure 2.1 Absorbance spectra of a) reagent blank and 
b) PL HC1 (21 mg/1).
Figure 2.2 Changes in the Figure 2.3 Rate of change 
absorption spectrum with in absorbance at 408 nm 
time . (PL HC1 21 mg/1).
A typical calibration curve making use of 5 PL standards 
of different concentration yielded the following 
equation :
Absorbance = 0.0278 Concentration + 0.0085 
A regression coefficient of 0.9997 was determined, thus 
indicating good linearity and adherence to the Beer- 
Lambert law (refer to Appendix la for calibration data). 
A detection limit of 0.33 mg/1 was calculated (Appendix
20
Ib) . Precision was assessed by analysing 5 sample 
replicates from an analytical sample containing 10.7 
mg/1 PL HC1. The results are summarized in Table 2.1.
Table 2.1 Determination of precision
Sample replicate A B C D E
Concentration 10.8 10.9 10.8 10.7 10.7
(mg/1 )
A mean of 10.78 mg/1 with a relative standard deviation 
of 0.78% and a standard error of 0.037 was determined. 
A confidence interval of 100-101.5% at the 90% 
confidence level was calculated for the assay.
To determine accuracy, samples containing various 
amounts of PL HC1 were assayed (Table 2.2).
Table 2.2 Determination of accuracy
Sample A B C D
True Concentration 10.7 6.5 13.5 2 2 .3
(mg/1 )
Measured Concentration 10.8 6.6 13.3 22.5
(mg/1 )
An average relative bias of 0.47% was calculated showing 
that the method tends to slightly over estimate the PL 
concentration. However this was not found to be 
significant as determined by the student-t test at the 
95% level of confidence.
No interference was observed when pyridoxine,
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nicotinamide or thiamine (up to 10mg/l respectively) 
were present in the sample solution. Samples extracted 
from mixtures containing common tableting excipients 
(microcrystalline cellulose, starch, lactose and 
magnesium stearate up to 50 mg/1 respectively) also did 
not show any increased absorption. However, the presence 
of riboflavin, folic acid and ascorbic acid tended to 
increase absorbance values. It is remarkable that no 
interference from pyridoxine was observed. In the 
procedures reported by Nirmalchandar et al(1987) and 
Hochberg et al (1944) interference from PN was 
eliminated by the addition of boric acid. Boric acid 
complexes with the primary alcohol groups of PN thus 
preventing the interaction of PN with the coupling 
agent. Boric acid addition does not appear to be 
necessary in the current procedure. A possible reason 
for this is the relatively low pH (2.5) used in this 
method. The method of Nirmalchandar et__al(1987) 
specifies a pH of 8 for the coupling reaction of PN with 
4-aminoantipyrine.
In summary, the above method has been shown to be 
suitably sensitive, accurate and precise for the 
determination of PL in solution and also in the presence 
of excipients.
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2.3 THIN LAYER CHROMATOGRAPHIC ANALYSIS OF
PYRIDOXAL HCL
2.3.1 BACKGROUND
TLC is a popular technique for the analysis of vitamin 
B6. Indications of this are the detailed reviews on the 
TLC analysis of vitamin B6 published by several authors 
(Bolliger, 1965; Bolliger and Konig, 1969; Ahrens and 
Kortnyk, 1970; Coburn, 1986). Both cellulose and silica 
gel layers have been used, but it is clear from the 
reviews that silica gel stationary phases are best 
suited for the analysis of vitamin Bs.
A common problem in the TLC analysis of PL HC1 is the 
instability of PL in aliphatic alcohols. In acidic and 
neutral solutions PL exists as an hemiacetal and readily 
reacts with alcohols such as methanol and ethanol, 
forming PL methyl or ethyl acetal respectively 
(Nurnberg, 1961; Kortnyk and Singh, 1963) (Figure 2.4). 
The common practice of using alcohol as a rapidly 
evaporating sample application solvent thus has to be 
avoided, as the chromatograms usually show multiple 
zones corresponding to the hemiacetal, the full acetal 
and/or the free aldehyde (Nurnberg, 1961).
Figure 2.4 Hemiacetal and full acetal formation in PL.
23
By using water as the sample solvent this problem can be 
avoided , although sample application becomes more 
difficult. However, acetal formation may also occur 
during chromatography. Many mobile phases described for 
the chromatography of Bs, including PL, contain 
substantial amounts of either methanol, ethanol, 
propanol, n-butanol, tert-butanol, iso amyl alcohol or 
combinations of these (Ahrens and Kortnyk, 1970; Coburn, 
1986). Acetal formation may be overcome by 
prechromatographic derivatization of PL HC1. This can be 
achieved with carbonyl reagents such as phenylhydrazine, 
hydroxylamine and semicarbazide (Ahrens and Kortnyk, 
1970). Alternatively PL can be completely converted to 
its methyl acetal by refluxing in methanol for 1 hour 
(Nurnberg, 1961) . However, for the analysis of numerous 
small samples(< 2 ml), refluxing in methanol is time 
consuming and impractical. Furthermore the reliability 
of these derivatization reactions in complex biological 
and pharmaceutical samples has been questioned (Coburn, 
1986) .
Eleven solvent systems previously reported to yield 
successful separations of PL on silica gel were 
therefore investigated with the aim of finding a 
stability indicating TLC method that meets the following 
requirements:
i) Suitability for the separation and
identification of PL and breakdown products.
ii) Overcome the need for prechromatographic
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derivatization
iii) Suitability for detection by UV light.
2.3.2 METHODOLOGY
2.3.2.1 MATERIALS AND EQUIPMENT
Only analytical grade solvents (listed in table 2.3) and 
double distilled water (Milli Q system, Millipore, 
Bedford M.A.) were used. PL HC1 (Fluka, Buchs) was used 
to prepare the PL standards. For the excipient mixtures 
PL HC1 (approximately 10 mg) was mixed with 50 mg of 
Avicel 101 (FMC Corp., Philadelphia PA), Ludipress
(BASF, Ludwigshafen) or mannitol (Riedel de Haen, 
Seelze). Samples were applied to silica gel plates (HF 
60, 20x20, E Merck, Darmstadt) with a microlitre syringe 
(Hamilton, Bonaduz). Standard rectangular glass tanks 
with lids (N-tank, Camag, Muttenz) lined with absorbent 
paper were used for development. A photographic stand 
with UV light source (Reprostar, Camag, Muttenz) and a 
35 mm camera (Minolta XGE) were used to observe and 
photograph the chromatoplates.
2.3.2.2 PROCEDURE
PL standards were prepared by dissolving 10 mg PL HC1 in 
2 ml of water. To obtain samples containing breakdown 
products, PL HC1 (10 mg) and PL HCl-excipient mixtures 
in open vials were stored in a hygrostat containing a 
saturated NaCl solution (aproximately 75% relative 
humidity (RH)) at 55°C for 2 weeks. Distilled water (2
25
ml) was then added to the PL samples. PL-excipient 
mixture samples were prepared by adding 5 ml distilled 
water, centrifuging for 5 minutes and filtering the 
supernatant through a 0.45 pm membrane (MiIlex HV, 
Millipore, Bedford M.A.). 1 pi of each standard solution 
and 2 .5 F1 of excipient sample solutions were applied to 
the origin of a silica gel chromatoplate. Before use the 
plate was prewashed in a chloroform : methanol (1 :1 ) 
mixture, dried at 70°C for 30 minutes and then allowed to 
eguilibrate in laboratory air. Development was effected 
in mobile phase saturated glass tanks. The mobile phases 
which were evaluated are listed in Table 2.3. Solvent 
strength parameters (E0) were calculated for the mobile 
phases according to the values provided by Snyder 
(Wells, 1988e) (Appendix Ic) . The solvent migration 
distance was limited to 12 cm for all systems. After 
development the plates were air dried and briefly 
exposed to diethylamine vapour. The chromatograms were 
then observed and photographed under UV light (256 and 
366 nm).
2.3.2.3 RESULTS AND DISCUSSION
Of the 11 solvent systems investigated, only one system 
(methanol : chloroform, 25 : 75) (Ahrens and Kortnyk, 
1970) fulfilled all the criteria (Table 2.3). The 
other systems either showed inadequate resolution or 
additional zones, probably due to acetal formation. The 
methanol : chloroform (25 : 75) system yielded compact 
dark blue/black zones with R, values of 0.46-0.50 when
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Table 2.3 Evaluation of various solvent systems for the analysis 
of PL HC1
Mobile
Phase
Eo Resolution Rf Time (mins
Degradation
Products
References
A 0.54 good
resolution
0.46 45 3 distinct 
zones
Ahrens and
Kortnyk
(1970)
B — marked tailing 
zone is poorly 
visible
0.54 50 broad tail 
is visible 
at 366 nm
Bolliger
(1965)
C 0.59 good
resolution but 
multiple zones 
due to acetal 
formation
0.47 65 broad tail 
is visible
Puech et 
al, (1981)
D 0.56 marked tailing 0.32 60 poorly
visible
Nuernberg
(1961)
E 0.57 marked tailing 0.31 50 poorly
visible
Coburn
(1986)
F 0.40 no elution 0 60 - Coburn 
(1986)
G elution as 2 
distinct zones 
slight tailing
0.47 180 good
resolution
Coburn
(1986)
H - elution as 2 
zones
0.57 150 good
resolution
Coburn 
(1986)
I 0.59 only partial 
resolution
0.25 45 — Dement'eva 
et al.
(1968)
J - marked tailing 0.8 
0.71
60 Broad tail 
is visible
Me Coy et 
31,(1979)
K 0.58 elution as 
multiple zones
0.4 45 good
resolution
experiment­
al system *
Key: A chloroform: methanol (75:25); B 25% ammonia: water (1:139)
C chloroform: 2-propanol: methanol: water (58:30:10:2); D acetone 
followed by acetone: dioxane: 25% ammonia (45:45:10); E acetone 
followed by acetone: ethanol (95: 5); F chloroform: ethanol (99:1) 
G 1-butanol: 1M acetic acid (5:1); H water: acetone: tert-butanol: 
acetic acid (20:35:40:5); I ethyl acetate: acetone: 25% ammonia 
(20:10:1.5); J Isoamyl alcohol: acetone: water: diethylamine (24: 
18:6:8) followed by 2-butanol: ethanol: 25% ammonia: isoamyl alcohol: 
diethylamine (20:6:7:7:2); K chloroform: ethanol: acetic acid: water 
(54:27:9:4); E„ solvent strength parameter; R* relative migration 
distance.
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viewed at 256 nra. At 366 nm PL is visible as a bright 
blue/yellow zone. Decomposition products are visible as 
three distinct zones with a long tail behind the PL zone 
(Figure 2.5). Decomposition products were also visible 
in the chromatograms of the PL-excipient mixtures 
subjected to accelerated ageing (Figure 2.6), indicating 
the methods suitability for use in excipient 
compatibility testing. Pyridoxine (PN) was also readily 
separated by this method (Rf 0.37-0.41) and could thus be 
used as an internal standard. The method is also 
suitable as a rapid identity test to distinguish between 
PL and PN.
The study of the various mobile phases indicated that 
acetone based mobile phases were generally not suitable. 
It appears that good resolution can be achieved with 
solvent systems containing a substantial amount of 
alcohol with E0 values between 0.5 - 0.6 . However, the 
ratio of chloroform to alcohol and the absence of any 
strong acids is critical to avoid acetal formation.
The observation that a simple mobile phase of chloroform 
and methanol (75 : 25) prevented acetal formation is 
consistent with findings made during Karl Fischer 
titration of aldehydes. It has been found that when 
titrating aldehydes in methanol, acetal formation can be 
suppressed by substituting a large portion of the 
methanol (at least 50%) with chloroform (Imfanger and 
Schauwecker, 1984).
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Figure 2.5 Chromatogram of PL standard (1) and degraded 
PL (2) viewed at (a)366 nm and (b) 254 nm.
Figure 2.6 Chromatogram of PL standard (1), PL stored 
with Ludipress (2), mannitol (3) and Avicel (4).
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This study once again indicates that the reactivity of 
drugs containing aldehyde and hemiacetal functional 
groups can give rise not only to stability- but also to 
analytical problems. The solvent system first reported 
by Ahrens and Kortnyk (1970) provides a good separation 
on a standard silica gel stationary phase and can be 
used as a simple inexpensive stability screening test.
2.4 HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ANALYSIS 
OF PYRIDOXAL HC1
2.4.1 OVERVIEW OF EXISTING METHODS
The HPLC methods available for the analysis of vitamin 
B6 either make use of ion exchange- or reverse phase 
chromatography. Very successful and sensitive anion and 
cation exchange methods have been reported (Vanderslice 
et al. 1981; Coburn and Mahuren, 1983; Lui et al. 1985) . 
However, these methods require sophisticated equipment 
and procedures such as column switching, the use of 
ternary solvents and post column derivatization. Such 
methods, although very sensitive, are not ideally suited 
for preformulation studies and for routine analysis of 
pharmaceutical dosage forms.
Reverse phase chromatography, on the other hand, is a 
simpler and more versatile technique. A number of 
procedures have been reported using this mode of 
separation (Morita and Mizuno, 1980; Lim et al. 1980;
O'Reilly et al. 1980; Pierotti et al. 1984; Tryfiates
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and Sattsangi, 1982). Some of these methods do not 
completely separate PL and PN, but this can easily be 
remedied with ion pairing reagents such as sodium octane 
sulfonate (Tryfiates and Sattsangi 1982). These methods 
are generally not sensitive enough for B6 vitamer plasma 
analysis as UV detection is used. However, this is 
adequate for the analysis of pharmaceutical samples. 
Sensitivity can be further increased by using 
fluorimetric detection and derivatization (Gregory and 
Feldstein, 1985; Ubbink et alf 1985; Hollins and 
Henderson, 1986; McChrisely et al. 1988).
For the preformulation study of PL HCl a simple, 
quantitative stability indicating method for the 
analysis of PL HCL in pharmaceutical samples was 
required. For this purpose a reverse phase, ion pairing 
method based on the procedure reported by Tryfiates and 
Sattsangi (1982) was developed.
2.4.2 METHODOLOGY
2.4.2.1 MATERIALS AND EQUIPMENT
The following analytical or HPLC grade materials were 
used: PL HCl (Fluka, Buchs), PN HCl 99.7% pure (Roche, 
Isando), 2-propanol (Merck, Darmstadt), triethylamine 
(Merck, Darmstadt), acetic acid (Merck, Darmstadt),PIC 
B7 and PIC B8 (sodium heptane- and sodium octane 
sulfonate) (Waters Associates, Milford, MA.). Double 
distilled water (Milli Q system, Millipore, Bedford, MA)
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was used throughout. The following excipients were used 
to simulate analytical samples: Methyl cellulose 25 cp 
USP (Fluka, Buchs), Eudragit RSPM (Rohm Pharma, 
Weiterstadt), mannitol (Riedel de Haen, Seelze) and 
magnesium stearate (Fluka, Buchs).
Analyses were carried out on a System Gold (Beckman, 
San Ramon, CA. ) liquid chromatograph equipped with an 
Altex (Beckman) 210A injector valve with a 20 pi loop, 
a model 126 programmable solvent delivery module and a 
model 168 diode array detector. The system was fitted 
with a Beckman Ultrasphere ODS (particle size 5 pm, 4.6 
mm id., 15 cm) analytical column. Model P1000 and P5000 
digital micropipettes (Pipetman, Gilson, Villiers-le- 
bel) were used to make the necessary dilutions.
2.4.2.2 PROCEDURE
To prepare the internal standard approximately 10 mg of 
PN HC1 was accurately weighed and dissolved in 100 ml of 
water. A stock solution of PL HC1 was prepared by 
dissolving approximately 10 mg of PL HC1, accurately 
weighed, in 100 ml of distilled water. PL HC1 standards 
ranging from 0.05 to 0.0001 mg/ml were prepared in 10 ml 
volumetric flasks by taking appropriate aliquots of 
stock solution, adding 1 ml of internal standard 
solution and making up to volume with distilled water. 
Analytical samples consisted either of PL HC1 powder or 
PL HCl-excipient mixtures exposed to various 
environmental conditions. These samples were added to
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100 ml volumetric flasks, made up to volume with water 
and shaken for 10 minutes. An aliquot (3 ml) of this 
solution was passed through a 0.45 pm filter membrane 
(Millex HV, Millipore, Bedford, MA.). The procedure 
described for the preparation of PL HCl solutions was 
then followed. Standards and samples were refiltered 
through a 0.45 pm membrane before injection onto the 
column. All solutions were prepared in red light and 
stored in closed bottles, overlayed with nitrogen, in a 
refrigerator. PL HCl standards were prepared on a daily 
basis. Acidic and neutral PN solutions show good 
stability if protected from light (Shephard and 
Labradarios, 1986). The internal standard was therefore 
prepared on a weekly basis.
The mobile phase (A) was composed of 10% 2-propanol and 
a buffer consisting of 0.09% acetic acid, 0.1% 
triethylamine and a mixture of sodium heptane sulfonate 
and sodium octane sulfonate (0.004M). Two additional 
mobile phases (B and C) were prepared for purposes of 
comparison. Solvent B consisted of 10% 2-propanol and 
0.09% acetic acid as described by Tryfiates and 
Sattsangi (1982). Mobile phase C was identical to mobile 
phase A except that no triethylamine was added. All 
solvents were filtered through a 0.22 pm filter (Type 
GV, Millipore, Bedford, MA.) and degassed before use. A 
solvent flow of 1.0 ml/min and a pressure of 
approximately 1.1 MPa was maintained. Prior to use, the 
column was equilibrated by passing 15 ml of solvent
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through the system. The eluent was monitored at 288 nm 
and 313 nm for comparative purposes and the detector was 
programmed to analyse peaks using the purity scan mode.
The procedure was compared to the original method of 
Tryfiates and Sattsangi (1982) and the specificity, 
linearity, precision and accuracy of the method was 
assessed according to the guidelines of Cavenaghi et al 
(1987) and Boehlert (1984). For this purpose samples 
consisting of PL HC1 (approximately 10 mg accurately 
weighed), methyl cellulose (50 mg), Eudragit RSPM (50 
mg) and mannitol (50 mg) were used.
2.4.3 RESULTS AND DISCUSSION
The chromatograms obtained after injection of the PL 
standard and sample solutions are shown in Figure 2.7.
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FIGURE 2.7 Chromatograms of: a) PL standard, 1 PL 
(3.39 mins), 2 PN (4.91 mins); b) PL sample, 1 PL 
(3.46 mins), 2 PN (5.01 mins); c) PL sample with 
decomposition products, 1 PL (3.38 mins), 2 PN 
(4.93 mins).
The peaks were identified by their retention times and 
peak purity was confirmed by scanning and comparing the 
UV spectra of the leading slopes, the apices and the
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trailing slopes of the peaks (Figure 2 .8 ). Correlation 
coefficients (r) for the normalized scans were better 
than 0.9999, indicating peak purity.
Wavelength (nm) Wavelength (nm)
Figure 2.8 UV spectra of the leading edges, the apices 
and the trailing edges of the peaks, a) PL; b) PN.
Figure 2.7c shows the separation of PL from its 
decomposition products. As far as could be ascertained 
the pathway of PL HC1 decomposition is not documented in 
the literature. A possible route of decomposition is 
discussed in chapter 5. However, the decomposition 
products were not identified. Part of the problem was 
that the decomposition products did not elute as well 
defined peaks. Furthermore some of the products seemed 
to elute at the solvent front. Stability was therefore 
monitored by measuring the decrease in the PL peak and 
using the purity scan mode detector to confirm the 
integrity of the PL and PN peaks.
The method was found to be linear over the concentration
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range of 0 . 0 0 0 5  to 0 .1 mg/ml. Seven concentration levels 
were used and three injections were made per 
concentration level. The equation for a typical 
calibration curve is y = 0 . 0 1 0 8 2 4 X  + 0 . 0 0 0 2 4 1  , where x 
is the ratio of the PL and PN peak areas and y refers to 
the PL concentration. A regression coefficient of r = 
0 . 9 9 9 5  was determined. No detector response was obtained 
for the lowest concentration standard (0.0001 mg/ml). 
The sensitivity limit therefore lies between 0 . 0 0 0 1  and 
0 . 0 0 0 5  mg/ml. The relevant calibration data can be 
found in Appendix Id.
Precision was assessed from the analysis of 5 sample 
replicates from an analytical sample containing 10.4 
mg/ml PL HC1. The results are tabulated below (Table 
2.4) .
Table 2.4 Precision analysis
Sample replicate A B O D E
Concentration 
(mg/ml) 10"2
10.1 10.4 10.1 10.3 10.3
A mean of 0.01022 mg/ml with a standard error of 0.00006 
was determined. From this the 90% confidence interval 
for the assay was calculated to be 97.2%-99.7% .
To determine accuracy, five PL-excipient mixtures, each 
containing 10.0 mg PL HC1, were assayed (Table 2.5). A 
mean of 0.01002 mg/ml was determined. From this a
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relative bias of 0.2% was calculated. This was not 
significant as determined by the students t-test (95% 
confidence level). Recovery from the powder mixtures is 
therefore essentially complete and the method is 
accurate.
Table 2.5 Accuracy determination
Sample A B C D E
Concentration 
(mg/ml) 10-2
10.2 10.0 9.8 10.2 9.9
The original method of Tryfiates and Sattsangi (1982) 
requires that after 5 minutes elution time a solvent 
switch is made to solvent B which is free of counter 
ions and that elution be monitored at 313 nm. Their 
method did not employ triethylamine in the mobile phase. 
Monitoring elution at 288 nm clearly resulted in 
increased sensitivity (Figure 2.9).
Figure 2.9 Detector response for PL sample at a) 288 nm 
and b) 313 nm.
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This is not surprising as 288nm coincides with the UV 
absorption maxima of PL and PN in the mobile phase 
(Figure 2 .1 0 ).
Figure 2.10 UV spectra of PL and PN in the 
mobile phase.
Switching solvents at 5 mins, elution time was found to 
be unnecessary. This resulted in a considerable time 
saving as the need to re-equilibrate the column with the 
first solvent before each new run was eliminated. 
Addition of a small amount of triethylamine (0.1%) 
produced narrower, sharper peaks and reduced retention 
times by approximately 1 minute.
2.4.4 CONCLUSION
Compared to the procedure of Tryfiates and Sattsangi 
(1982), the adapted method utilizes a simpler mobile 
phase and does not require lengthy column re­
equilibration before each run . The method also has a 
shorter elution time. Thus a considerable saving in time 
and solvents was achieved. An improvement was also made
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to the sensitivity of the method. The accuracy, 
precision and selectivity of the procedure were found to 
be suitable. Ideally a stability indicating method 
should enable the quantitation and identification of 
both the drug and the decomposition products. It was not 
possible to identify and quantitate the decomposition 
products. However, PL and PN peak purity can be 
ascertained with the aid of the diode array detector. 
Therefore it is felt that the method is a suitable 
stability indicating assay for preformulation purposes.
2.5 DETERMINATION OF WATER CONTENT IN PYRIDOXAL HC1 
BY KARL FISCHER ANALYSIS
2.5.1 THEORETICAL BACKGROUND
The Karl Fischer titration is based on the reaction of 
water with iodine in the presence of sulfur dioxide and 
a suitable base. The process can be summarized by the 
following equation:
H20 + I2+ S02+ CH30H + 3RN----- KRNH]S0 4CH3 +2 [RNH]I
RN = Base
During an accurate titration, the end point is usually 
reached within two minutes. To avoid a drifting end 
point samples have to be prepared so that the water is 
freely available and interfering side reactions must be 
suppressed. Of particular relevance to the moisture 
determination in PL HC1 is the reaction of aldehydes 
with the non aqueous solvent (ie. methanol) resulting in 
acetal formation :
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RCO + CH30H ------ > RCOCH3 + H20
In some aldehydes the rate of reaction is quick enough 
to interfere with the titration. However, this reaction 
can be readily suppressed by partially substituting the 
methanol with chloroform (Infanger and Schauwecker, 
1984). An additional factor which may have to be 
considered during method development is the reaction pH: 
the Karl Fischer reaction only proceeds smoothly in the 
range between pH 4 and 7.
2.5.2 METHODOLOGY
2.5.2.1 MATERIALS AND EQUIPMENT
A Karl Fischer titrant containing iodine, sulfur dioxide 
and pyridine (Riedel de Haen, Seelze) was used. A 
mixture of specially dried methanol (Carlo Erba, Milan) 
and chloroform (BDH, Poole) was used as titration 
solvent. The moisture determinations were made with a 
DL18 Karl Fischer titrator (Mettler, Greifensee).
2.5.2.2 PROCEDURE
Methanol and chloroform (20 ml of each) were introduced 
into the titration vessel and pretitrated to eliminate 
any traces of water. The apparatus was then calibrated 
with 50 mg of water (accurately weighed). Accurately 
weighed samples (approximately 500 mg) of PL HC1 (Fluka, 
Buchs) were then introduced into the titration vessel. 
90 seconds stirring time was allowed before initiating 
the titration. Accuracy and precision were determined by
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analysing samples of pure water and samples of PL HC1 
(Fluka, Buchs) respectively.
2.5.3 RESULTS AND DISCUSSION
It was found that a stir time of 60-90 seconds before 
titration was necessary to ensure that water was freely 
available. Reproducible end points were then reached 
within 2 minutes. However, in PL HC1 samples with low 
moisture contents (0 .1-0 .5%) the end point was reached 
considerably earlier. It therefore appears that the use 
of chloroform as an auxilliary solvent was effective in 
suppressing acetal formation. The method was deemed 
accurate, provided water is freely available. A relative 
bias of -0.0005% was determined (Table 2.6).
Table 2.6 Determination of accuracy. Analysis of pure 
water samples
Sample % Water content
1 99.87
2 100.10
3 99.89
mean 99.95
bias 0.05
Using the students t-test the bias was found not to be 
significant at the 95% confidence level.Precision was 
also deemed suitable. Analysis of 3 standard samples of 
PL HC1 provided a mean of 0.218% with a standard error 
of 0.0046. A 95% confidence interval of 0.198-0.238% was 
calculated (Table 2.7).
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Table 2.7 Determination of precision. Analysis of PL 
HC1 samples.
Sample % Water content
1 0.227
2 0.212
3 0.214
mean 0.218
standard deviation 0.0079
standard error 0.0046
The method is therefore suitable for the determination 
of equilibrium moisture contents in PL HC1.
2.6 THERMAL ANALYSIS OF PYRIDOXAL HC1
2.6.1 THEORETICAL BACKGROUND
The thermal analytical techniques used in this study 
were DSC and TGA. These two techniques are often used in 
conjunction and appear to be the major thermal 
techniques used in pharmaceutical analysis (Giron, 
1986). With DSC, thermal energy changes occurring in a 
sample which is subjected to a controlled temperature 
change, can be measured quantitatively. This allows the 
monitoring of a wide range of temperature induced 
exothermic and endothermic physical and chemical 
phenomena. Phenomena which can be detected as exothermic 
peaks on a DSC thermogram include adsorption, 
crystalline transitions, crystallization (including 
devitrification), oxidation reactions, decomposition 
reactions, redox reactions and solid state reactions. 
However, decomposition reactions, redox reactions, solid
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state reactions and chemical reactions in general may 
also be endothermic. Events which are specifically 
endothermic include desorption, fusion, vapourization, 
sublimation, glass transitions, reduction reactions, 
dehydration and desolvation (Dodd and Tonge, 1987a).
The energies measured in DSC are small and experi­
mental conditions are therefore a major factor 
determining the actual response recorded by the 
instrument. Experimental conditions which have to be 
considered include sample mass, sample geometry, heating 
rate and the ambient sample atmosphere (Giron-Forest, 
1984). Generally larger sample masses result in poorer 
resolution of the thermogram (Giron-Forest, 1984). In 
large samples there is a significant temperature 
gradient and volatile products may not escape as easily. 
Typical sample masses for DSC are therefore usually in 
the region of 1-10 mg (Dodd and Tonge, 1987b). Sample 
geometry may also significantly affect resolution and 
reproducibility. Powders should be uniform, finely 
subdivided and packed into the pan as a thin layer, thus 
making maximum thermal contact with the bottom of the 
pan and avoiding large temperature gradients. A low 
heating rate (<10°C/min) is important for accurate 
quantitative measurement and for the resolution of 
thermal events which occur within a few degrees of each 
other (Dodd and Tonge, 1987b; Giron-Forest, 1984). The 
ambient sample atmosphere can also significantly affect 
the nature of the observation. To prevent oxidation
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reactions, it is common to continuously purge the DSC 
cell with nitrogen. This then makes the hermetic sealing 
of pans unnecessary. Such conditions may assist in 
observing evaporation and desolvation phenomena. On the 
other hand, degradation and oxidation reactions can also 
be suppressed by hermetically sealing sample pans. 
Experiments can then be conducted in a static air 
atmosphere (Mettler Instrumentation mannual).
Instrumental factors over which the analyst usually has 
little control include the type of thermocouples and 
the construction of the platform on which the 
thermocouples are seated (glass and porcelain sensors 
tend to be more sensitive than the more durable, 
traditional metal sensors). A further factor which 
varies with each type of instrument is the construction 
of the sample pan.
In TGA mass changes in a sample subjected to a 
controlled temperature change are monitored. This allows 
the detection of any temperature dependent phenomena 
which result in mass changes, eg chemical reactions, 
adsorption, desorption, desolvation and evaporation. 
Many of the factors affecting DSC also significantly 
affect the observations made by TGA: For optimum 
resolution a small sample (a few mg) packed in a thin 
layer and heated at a slow heating rate(< 10°C) is 
required. In addition the ambient atmosphere profoundly 
affects TGA response. TGA sample containers have to be
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open in order to allow mass transfer( eg. loss of 
volatile substances). If oxidation reactions are to be 
avoided, purging with nitrogen gas is essential. 
Conversely if oxidation is to be studied, purging with 
oxygen or compressed air should be considered.
As part of preformulation investigations simple thermal 
methods have been developed to study physical changes in 
PL HC1 and in particular the occurrance of polymorphism, 
solvate formation (pseudopolymorphism) and amorphous 
states. In addition DSC has been utilized in studying 
drug excipient interactions.
2.6.2 METHODOLOGY
2.6.2.1 MATERIALS AND EQUIPMENT
PL HC1 (Fluka, Buchs) was used throughout this 
experiment. DSC was carried out in standard aluminium 
pans on a Mettler (Greifensee) TA3000 system equipped 
with a DSC 20 cell containing a glass sensor. TGA was 
performed in open platinum pans on a Du Pont 9900 
system.
2.6.2.2 PROCEDURE
The DSC system was calibrated against a pure indium 
standard (99.999% pure, mp 156.6°C), as well as against 
pure lead and zinc standards. PL HC1 samples (2-5 mg) 
were accurately weighed into aluminium pans and slightly 
tamped to form thin layers. The pans were then
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hermetically sealed and heated from 30°C to 200°C at 
rates of 20, 10 and 7°C/min. A sealed, empty aluminium 
pan was used as a reference. For purposes of comparison 
samples were then also analysed in an atmosphere of 
flowing nitrogen (20 ml/min). Here the aluminium sample 
pan lids were perforated to allow free circulation of 
nitrogen throughout the system. For TGA, samples (2-5 
mg) were packed thinly into the open pans and analysed 
in an atmosphere of flowing nitrogen (20 ml/min) at the 
most suitable heating rate.
2.6.3 RESULTS AND DISCUSSION
Figure 2.11 shows the DSC thermograms obtained at 
different heating rates in a static air atmosphere 
(hermetic seal). PL HC1 has two endothermic peaks 
separated by an asymmetric, concavely sloping exotherm 
occurring above 170°C. A change in heating rate does not 
obscure any of the essential features of the curve. 
However, at increased heating rates there is a clear 
trend towards higher peak temperatures and areas 
(enthalpies). These are therefore procedural peak 
temperatures and enthalpies rather than actual 
temperatures and enthalpies of transition. However, the 
values obtained at lower heating rates tend to reflect 
the true values. This a general trend observed for DSC 
(Dodd and Tonge, 1987b).
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Temperature 'C
Figure 2.11 DSC thermograms of PL HC1 heated at 
a) 7°C/min; b) 10°C/min; c)20°C/min.
The thermogram observed for PL HC1 is typical of a 
polymorphic transition. Three types of DSC curves which 
may indicate polymorphic transitions have been 
identified (Giron, 1986; Giron-Forest, 1984) (Figure 
2 . 12 ) .
Figure 2.12 Manifestations of polymorphism, 
a) solid-solid transition before melting; b) melting of 
each polymorph without transition to the more stable 
form; c) melting of the metastable form and re­
crystallization of the stable form (Giron-Forest, 1984)
In all graphs the stable polymorph is denoted as "I" and
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the metastable forms are denoted by higher roman 
numerals (eg. II).
PL HC1 clearly resembles the curve in Figure 2.12 c). 
This phenomenon involves melting of metastable form II 
and recrystallization of form I from the melt. Such 
curves have also been observed for the polymorphic 
transitions of sulfamethoxypyridazine (Maury et al. 
1985), carbamazepine (Krahn and Mielck, 1987) and a 
dibenzoxapine component (Gibbs et al. 1976). Further
evidence of polymorphism in PL HC1 is discussed in 
section 3.3.3.3.2).
Figure 2.13 a) Typical thermogram of PL HCl 
hermetically sealed in static air atmosphere, b) Typical 
thermogram of PL HCl in flowing nitrogen (7°C/min heating 
rate in both cases).
Based on these studies a heating rate of 7°C/min was 
chosen for all future experiments as this gave good and 
reproducible resolutions of the various thermal events 
occurring in PL HCl (Figure 2.13a). Lower heating rates 
were not investigated as these were considered 
impractical.
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In an open pan under flowing nitrogen the thermogram has 
just one broad exothermic melting peak at approximately 
182°C( Figure 2.13b). Onset of melting occurs at 
approximately the same temperature as in the static air 
atmosphere (155°C), but it appears that the exothermic 
recrystallization phase is suppressed in a flowing 
nitrogen atmosphere, resulting in a single broad 
endothermic peak. A further significant feature of the 
curve is the upward drift occurring at 220°C. This is 
indicative of sample decomposition and is probably the 
result of pyrrolytic decomposition occurring in the 
molten phase. This is not observed in the static air 
atmosphere as degradation and oxidation reactions are 
suppressed in the closed system formed by the 
hermetically sealed pan (Mettler Instrumentation 
Mannual).
The TGA and DTGA (derivative thermogravimetric analysis) 
traces of PL HC1 obtained at 7°C/min in flowing nitrogen 
are shown in Figure 2.14.
Temperature (°C )
Figure 2.14 a) TGA and b) DTGA traces of PL HC1 
(7°C/min, flowing nitrogen)
As expected, these show a weight loss due to pyrrolytic
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decomposition occurring with the onset of melting. 
However, no other processes resulting in significant 
weight changes are evident.
It is therefore apparent that in DSC analysis a static 
air atmosphere in hermetically sealed pans provides a 
more detailed picture of the physical changes which 
occur in PL HC1 upon heating. However the thermal 
lability of PL HC1 is not adeguately reflected in this 
system. DSC analysis with a heating rate of 7°C/min in 
a static air atmosphere was therefore combined with TGA 
(7°C/min, flowing nitrogen 20 ml/min) to investigate any 
crystal transformations and solvates in PL HC1 (see 
section 3.3.3.3.2). However, to investigate excipient 
compatibility DSC analysis with nitrogen purging was 
used (chapter 5). This procedure provides a more 
accurate reflection of the stability characteristics of 
PL HC1 and also provides simpler thermograms of PL HCl. 
This is important as the thermograms of drug-excipient 
mixtures are often difficult to interpret due to the 
occurrance of many overlapping or interfering thermal 
features (van Dooren, 1983).
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CHAPTER THREE
3 THE SOLID STATE PROPERTIES OF PYRIDOXAI, HC1
3.1 INTRODUCTION
Drugs are most frequently administered as solid dosage 
forms. According to a recent survey (Wells, 1988b), 
tablets and capsules accounted for 58.8% of all dosage 
form types manufactured in the UK. Reasons for the 
popularity of the solid dosage form include the fact 
that it can be administered orally with a minimum of 
discomfort and inconvenience to the patient, thus 
improving compliance. Tablets and capsules can also be 
manufactured with relative ease and at low cost when 
compared to such dosage forms as sterile parenterals. In 
addition, they provide accurate dosing and tend to have 
good stability characteristics, enabling uncomplicated 
long term storage.
The investigation of solid state drug properties is 
therefore an important aspect of most preformulation 
studies. Solid state properties are defined here to
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include the molecular structure of the solid compound, 
its stability profiles, the crystal properties and other 
bulk characteristics (eg. surface morphology, 
hygroscopicity, particle size, bulk density and
compressibility).
The most basic characteristic of any drug substance is 
the molecular structure, as it affects all other 
physicochemical properties of the drug. The solid state 
characterization of PL HC1 was therefore initiated with 
an investigation of the molecular structure. This was 
followed by a bulk characterization consisting of a 
study of the crystal properties, particle 
characteristics and hygroscopicity .
3.2 THE MOLECULAR STRUCTURE OF PYRIDOXAL HC1 IN THE 
SOLID STATE
3.2.1 BACKGROUND
Rabinowitz and Snell (1948) demonstrated that vitamin B6 
is widely distributed in 3 forms in nature, namely 
pyridoxine (PN), pyridoxal (PL) and pyridoxamine (PM).
The view is widely held that these 3 vitamers differ 
structurally mainly in the nature of their 4- position 
functional groups, which may be an alcohol, aldehyde or 
amine moiety (Figure 1.2). However,in the case of PL 
this is not strictly correct. A fundamental 
characteristic of the aldehydes is their ability to 
react with alcohols, yielding acetals in the process. In
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PL this reaction can occur internally between the 4- 
formyl group and the neighbouring 5-methyl hydroxy group 
resulting in the formation of an internal hemiacetal 
(Figure 3.1) (Nurnberg, 1961).
Early studies of the structure of PL base using IR-, 
NMR- and UV spectroscopy showed that PL base exists as 
an internal hemiacetal in neutral and acidic solution, 
as well as in the solid state (Heinert and Martell, 
1959; Kortnyk and Singh, 1963; Metzler and Snell, 
1954). More recently X-ray diffraction techniques have 
been used to establish the solid state structure of PL 
base (Rao et al. 1982). These studies showed that PL
exists exclusively in the hemiacetal conformation as 
proposed by previous workers.
It is obvious that this structure differs markedly from 
that of the free aldehyde. Such differences in structure 
result in significant differences in physicochemical 
properties. However, only one author (Kortnyk, 1986) has 
provided data indicating that PL HC1 (the salt) could 
also exist as an internal hemiacetal. To confirm the 
molecular structure of the compound used in this 
preformulation study, PL HC1 was analysed by IR
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spectroscopy. IR spectroscopy is a particularly suitable 
method of analysis, as carbonyl functional groups show 
very characteristic and prominent peaks at approximately 
1700 cm"1 which are seldomly obscured (Morrison and 
Boyd, 1984). If present, the carbonyl group should 
therefore be easily identifiable. Similarly the "C-O-C" 
ether linkage of the hemiacetal yields very 
characteristic peaks.
3.2.2 METHODOLOGY
Pyridoxal HC1 (Fluka, Buchs) and potassium bromide 
(Uvistat,E Merck, Darmstadt) were used. The potassium 
bromide was dried at 50°C for two hours before use. 
Potassium bromide/PL HC1 pellets were compressed on a 
hydraulic press (Beckmann, San Ramon, CA) . Infrared 
absorption spectra (4000-4600 cm-1) were obtained with a 
Nicolet (Madison,WI) FDX IR spectrophotometer connected 
to a 5DX data processor.
3.2.3 RESULTS
The infra red spectrum of PL HC1 is shown in Figure 
3.2. Table 3.1 provides a summary of the absorption 
bands and a comparison with the data reported by Kortnyk
(1986).
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Figure 3.2 Infra-red spectrum of PL HC1 (KBr pellet).
Table 3.1 Characteristic infra-red absorption peaks and 
bands of PL HC1
Frequency 
and bands
of peaks 
(cm'1)
Assignment Frequency
reported by 
Kortnyk (1986) 
(cm'1)
1018 C-0 stretch 1000
1058
1083
1246
1261
hemiacetal ring, 
C-O-C stretch
several peaks 
at 1050 and 
1250
1445
1466
1556
pyridine ring 
vibrations
1430
1500
1570
1639-1643 ring vibrations 
representing C=N"H 
(HC1 peak)
1630-16660
2600-3032 phenolic hydroxyl 
group hydrogen 
bounded to 
pyridine vitrogen
2500-2900
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3.2.4 DISCUSSION
If PL HC1 were present in the free aldehyde form, a 
prominent peak in the region 1675-2000cm*1 would be 
expected. No such peak is evident. The only peak to come 
into consideration is the medium intensity band at 1639- 
1643cm"1. However, this is outside the normal range for 
"aldehyde peaks" and correlates well with Kortnyks 
assignment of the "hydrochloride peak" (due to ring 
vibrations representing C=N+H) . In addition, the acetal 
is confirmed by the characteristic high intensity peaks 
at approximately 1250, 1050 and 1000cm'1 .
The spectrum correlates well with the description and 
interpretation of the IR spectrum provided by Kortnyk 
(1986). The spectrum shows the characteristic signs of 
a hemiacetal. On the other hand there is no evidence of 
a carbonyl group. A molecular structure similar to that 
reported for PL base (Rao et al. 1982) appears to be
appropriate for PL HC1 (Figure 3.3).
0 (2)
O  Oxygen
Figure 3.3 Proposed structure of PL HC1. Adapted from 
Rao et al (1982).
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Similar to PL base, (Heinert and Martell,1958; Rao et 
al. 1982) , there are also clear indications of
intermolecular hydrogen bonding between the phenolic 
hydroxyl group and the pyridine nitrogen of adjacent 
molecules in PL HC1 (Table 3.1) . The similarity may be 
due to the fact that in both PL base and PL HC1 the 
pyridine nitrogen is protonated. Although not evident 
from the IR scans, it is likely that the phenolic 
hydroxyl group is also involved in intermolecular 
hydrogen bonding with the hydroxyl group of the 
hemiacetal ring as is the case for PL base (Rao et al. 
1982) .
i
3.3 BULK CHARACTERIZATION OF PYRIDOXAL HC1
3.3.1 OVERVIEW
Characterization of bulk properties such as particle 
size, bulk density, flowability, crystallinity and 
hygroscopicity is essential as bulk lots of drug often 
vary in these properties resulting in significant 
changes in stability, bioavailability and
manufacturability (Fiese and Hagen, 1986) . Especially 
important for tableting and encapsulation are 
flowability, bulk density and compressibility. However, 
the average dose of vitamin Bs per tablet seldomly 
exceeds 50mg (Bauernfeind and Miller, 1978). This 
represents only a small proportion of the bulk of a 
tablet. The bulk density, flowability and
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compressibility of PL HC1 were therefore not 
investigated as it is unlikely that small quantities of 
PL HC1 would significantly affect the tableting process 
and properties of the formulation or the final product.
3.3.2 FINE PARTICLE CHARACTERIZATION
3.3.2.1 THEORY
Surface area controlled processes and physicochemical 
properties such as dissolution, adsorption and chemical 
reactivity are directly affected by particle size 
distribution and shape. An example is the poorly soluble 
drug, griseofulvin, which shows increased 
bioavailability when administered in a finely subdivded 
state (Gibaldi, 1984). Particle size distribution is 
also important for formulation homogeneity and dose 
uniformity. This applies especially to drugs 
administered in low doses. Generally finer materials 
interdisperse more readily and more randomly (Wadke ei 
al, 1989).
However, size reduction may also result in disadvantages 
such as a larger surface area for chemical interaction 
with oxygen, moisture, light and excipients. An 
increased surface area also results in increased 
hygroscopicity and electrostatic agglomeration (Wadke 
al, 1989).
Numerous methods are available for particle sizing.
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These include light microscopy, electron microscopy, 
conductivity measurements (Coulter Counter ) and laser 
light scattering measurements (Royco Particle counter). 
The particle size distribution and surface morphology of 
PL HC1 were investigated by scanning electron microscopy 
(SEM). Particle shapes are discussed later (see
3.3.3.3.1 Crystal Habit).
3.3.2.2 METHODOLOGY
PL HC1 (Fluka Ag, Buchs) was dried at reduced pressure 
over phosphorus pentoxide (SARchem, Krugersdorp) for 24 
hours. The samples were then sputter coated with 
colloidal graphite before fine coating with a 
gold/platinum film. Photomicrographs were obtained with 
a Jeol (Tokyo) JSM-840 scanning electron microscope at 
15KV accelerating voltage. Particle sizes were measured 
on a series of 9 electron photomicrographs using Ferets 
diameter as an indicator of gross external dimension 
(Figure 3.4) (Wells, 1989f).
Figure 3.4 Various statistical particle diameters for 
the assessment of irregular particles. A, projected area 
diameter; C, maximum horizontal cord; F, Ferets 
diameter; M, Martins diameter. (F>C>M) Adapted from 
Wells (1989f).
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Particle size data was analyzed by means of a frequency 
distribution histogram and a log normal cumulative 
distribution curve. The geometric mean size (M) and the 
geometric standard deviation (crq ) were determined from 
the cumulative distribution curve. M can be read from 
the graph at 50% oversize and o g c a n  be calculated as 
follows:
crg = size at 16% (oversize) (Wells, 1989f) 
size at 50% (oversize)
3.3.2.3 RESUTS AND DISCUSSION
Typical scanning electron micrographs of PL HC1 are 
shown in figure 3.5. At low power magnification the 
marked agglomeration of the particles is clearly 
visible. In general, particle surfaces are smooth with 
occasional fissures in evidence.
Size analysis reveals a large proportion of smaller 
particles with sizes varying from 3 to 60 pm (Table 3.2 
and Figure 3.6). The skewed distribution was normalized 
by plotting particle size on a log scale. This yielded 
a typical sigmoidal cumulative distribution curve 
(Figure 3.7). The system thus follows the general model 
for particulate distribution as proposed by Hatch and 
Choate (1929).
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Figure 3.5 Scanning electron photomicrographs of PL 
HC1. A) x 500 magnification, B) x 950 magnification,
C) x 2700 magnification.
Table 3.2 Particle size analysis by SEM
Particle size 
(pm)
Particle
count
Cumulative
count
Cumulative
percentage
>40 9 9 6.1
30 - 40 12 21 14.2
20 - 30 21 42 28.4
10 - 20 55 97 65.5
5 - 1 0 43 140 94.6
0 - 5 8 148 100.0
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Using the cumulative distribution curve, the geometric 
mean particle size was estimated as 15.8 pm and a value 
of 1.78 was calculated for the geometric standard 
deviation (crg). A wide particle size distribution 
typically gives values >2 for og, whereas tight particle 
size distributions yield values for crg in the region of 
1.5 (Wells, 1989f).
Particle Size (pm)
Figure 3.6 Frequency distribution histogram of PL HC1 
particle size.
Figure 3.7 Cumulative distribution curve of PL HC1 
particle size.
Generally the experimental samples of PL HC1 show a
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particle size distribution typical of most particulate 
systems with a relatively low crg. Of the particles 
analysed, 66% fall into the range of 5 - 20 pm as 
measured by their Ferets diameter. Size uniformity 
could be increased further by milling. However, the 
present distribution can be regarded as suitably tight 
for a low potency drug administered in low doses.
3.3.3. THE CRYSTAL PROPERTIES OF PYRDOXAL HC1
3.3.3.1 THEORETICAL BACKGROUND
Similar to the molecular structure and fine particle 
characteristics, the crystalline characteristics of a 
drug may significantly influence the solubility and 
bioavailability and other important physicochemical 
properties . Important crystal properties relevant to 
pharmaceuticals have been outlined by Halebian (1975) 
(Figure 3.8).
chemical compound
habit internal structure
crystalline amorphous
I I
single entity molecular adducts
I I
polymorphs | |
nonstoichiometric stoichiometric
inclusion compounds solvates (hydrates) 
___________I
channel layer cage
(clathrate)
Figure 3.8 Outline of important crystal
characteristics.
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Two major properties highlighted by Halebian are the 
crystal habit (the external appearance of the crystal) 
and the internal structure (the molecular arrangement 
within the crystal). In crystalline solids the molecular 
arrangement is repetitive and shows long range order, 
while in amorphous solids no such repetitive order 
exists.
Many crystalline drugs also have more than one internal 
structure. These variations in crystal structure are 
known as polymorphs. At any one temperature only one 
crystal form will be stable, the other forms being 
metastable. Crystal variations known as solvates can 
also be produced by inclusion of solvent molecules in 
the crystal lattice.
Rao and his co-workers (Rao et al, 1982) have studied 
the crystal structure of PL base in detail. They found 
trigonal, prism shaped crystals and by X-ray diffraction 
were able to determine the exact intermolecular 
arrangement in PL. However, these results can not be 
directly applied to PL HC1 as chemical changes such as 
salt formation usually result in altered internal 
structures and crystal habits (Fiese and Hagen, 1986). 
Furthermore, it appears that polymorphic behaviour and 
solvate formation in PL HC1 have not been studied 
previously. A brief study of the crystal habit and of 
possible variations in the internal structure of PL HC1 
was therefore undertaken.
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3.3.3.2 METHODOLOGY
3.3.3.2.1 MATERIAL AND EQUIPMENT
Analytical grade PL HC1 (Fluka Ag, Buchs), acetone (E 
Merck, Darmstadt), chloroform (BDH, Poole) and methanol 
(BDH, Poole) were used. Double distilled water was 
obtained from a Milli-Q purifying apparatus (Millipore, 
Bedford M.A.). DSC was carried out in hermetically 
sealed standard aluminium pans on a Mettler (Greifensee) 
TA3 000 system equipped with a DSC 20 cell.
Thermogravimetric analyses were performed in platinum 
pans on a Du Pont 9900 system. Silica gel HF60 plates (E 
Merck, Darmstadt) were used for thin layer 
chromatography.
3.3.3.2.2 PROCEDURE
The crystal habits of PL HC1 were investigated with SEM 
as previously described (section 3.3.2.2). In order to 
investigate the existence of metastable and solvated 
forms, DSC analysis was carried out as described in 
chapter 2 (2.6.2) on PL HC1 samples recrystallized from 
acetone, chloroform and water. Aliphatic alcohols (eg 
methanol and ethanol) are commonly used for 
recrystallization. However, these could not be used for 
PL HC1 as they react with the hemiacetal resulting in 
the formation of methyl and ethyl acetals (Nurnberg, 
1961). In addition PL HCl was heated past the onset of 
melting (175°C) and then cooled before reheating by DSC. 
PL HCl was tested for decomposition during this
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treatment by using the previously detailed TLC procedure 
(section 2.3.2).
3.3.3.3 RESULTS AND DISCUSSION
3.3.3.3.1 CRYSTAL HABIT
PL HC1 ( Fluka AG, Buchs) exists as a mixture of large 
tabular or platy forms (approximately 60um diameter) and 
smaller anhedral prismatic forms (10-15um in diameter) 
(Figure 3.7). The smaller prismatic forms appear to have 
no clearly defined edges and plane faces. This large 
variation in size and shape may be due to impeded 
crystal growth during recrystallization (Halebian, 1975) . 
Alternatively the smaller particles may simply represent 
debris, formed when the larger plates were fractured. A 
further possibility is that the different crystal habits 
are a manifestation of polymorphism. This aspect is 
discussed in more detail below.
3.3.3.3.2 POLYMORPHISM AND SOLVATE FORMATION
The DSC thermogram of PL HC1 shows two endothermic peaks 
at ca. 170°C and 185°C separated by an exothermic peak at 
175°C (Figure 3.9a). An additional sample of PL HC1 was 
heated to 175°C, the approximate exothermic peak 
temperature, and then solidified by cooling. When this 
sample was reheated only one peak corresponding to the 
second endothermic peak of the initial thermogram 
(Figure 3.9a) appeared (Figure 3.9b). As discussed 
previously (section 2.6.1) such thermograms are
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characteristic of monotropic polymorphic transformations 
involving the melting of the metastable form II 
(endothermic process) and crystallization of the stable 
form I from the melt (exothermic process) (Giron-Forest, 
1984). The second endothermic peak denotes the melting 
of form I. TLC analysis of samples heated to 175°C in 
hermetically sealed pans indicated that no decomposition 
had occurred. Decomposition reactions and oxidation 
could thus be discounted as causes of the exothermic 
peak.
Temperature (°C )
Figure 3.9 DSC thermogram of a) PL HC1 as supplied 
and b) PL HC1 after heating and cooling
This is also borne out by the fact that the baseline 
remained stable after the second endotherm, indicating 
that the hermetic seal was sucessful in suppressing any 
oxidation or pyrrolysis. The presence of 
pseudopolymorphism was ruled out as no weight loss
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indicative of desolvation occurred before melting as 
illustrated by TGA analysis (see chapter 2, Figure 
2.14). The rapid weight loss coinciding with melting can 
be attributed to pyrrolytic decomposition accompanying 
the melting process. This is in agreement with 
previously published reports (Budavari et al. 1989).
Slight differences between the two forms were also 
observed by IR spectroscopy. Figure 3.10 shows the 
differences between PL HC1 (as supplied by Fluka) and PL 
HC1 after melting and resolidification by cooling. 
However, it could not be ascertained wether PL HCl 
exists only as form II or as a mixture of both 
polymorphs in its untreated state.
Figure 3.10 Differences in the IR spectra of a) PL HCl 
as supplied and b) PL HCl after heating and cooling.
The cooling and reheating studies failed to reveal any 
amorphous states of PL HCl. Amorphous compounds can 
often be produced by melting and then rapidly cooling
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the crystalline solids. The DSC curve of an amorphous 
solid shows a characteristic jump in the baseline be 
cause of the sudden change in heat capacity (cp) at the 
glass transition temperature (Tg) and an anomalous 
endothermic peak (heat capacity maximum) (Figure 3.11) 
(Fukuoka et al. 1986).
Figure 3.11 Characteristic features of the DSC curve of 
an amorphous solid. Adapted from Fukuoka et al (1986)
The presence of solvates was investigated by TGA and 
DSC. TGA has to be performed in open containers and PL 
decomposition is therefore expected to occur with the 
onset of melting (Budavari et al. 1989). However,
solvates should still be detectable as desolvation is 
expected to occur below the melting point. The TGA and 
DTGA traces of standard PL HC1 and PL HC1 recrystallized 
from water, acetone and chloroform clearly showed weight 
loss due to pyrrolytic decomposition occurring with the 
onset of melting (Figure 3.12). However, no significant 
weight loss was observed prior to melting, indicating 
the absence of any solvates. DSC thermograms of the 
recrystallized samples show only slight changes in peak 
shape and area when compared to the original untreated
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sample (Figure 3.13). The lack of desolvation peaks
confirms the absence of solvates. It is also apparent
from these DSC curves that it was not possible to
produce only stable form I crystals by
recrystallization.
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Figure 3.12 TGA and DTGA curves for PL HC1 
recrystallized from a) acetone, b) water, c) chloroform 
and d) untreated PL HC1
Temperature CC)
Figure 3.13 DSC thermograms of PL HC1 recrystallized 
from a) acetone, b) water, c) chloroform and d) 
untreated PL HC1
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3.3.3.4 CONCLUSION
Thermal analysis strongly indicates that at least two 
polymorphic forms of PL HC1 exist. It appears that the 
equilibrium between the polymorphs is monotropic. When 
PL HC1 was recrystallized from chloroform, acetone and 
water no solvates were formed. PL HC1 is a very water 
soluble compound (chapter 4) and has a rapid dis­
solution rate. A significant difference in bio- 
availability between the two polymorphs is therefore 
unlikely. For this reason no attempt was made to 
separately measure the intrinsic solubilities of the two 
crystal forms. The influence of environmental factors 
such as moisture and temperature on polymorphic 
behaviour will be considered in section 3.3.4.
3.3.4 THE HYGROSCOPICITY OF PYRIDOXAL HC1
3.3.4.1 INTRODUCTION
The term "Hygroscopicity" has no accepted definition as 
it encompasses both thermodynamic and kinetic components 
(Van Campen et al. 1980). A distinction can therefore be 
made between equilibrium hygroscopicity and dynamic 
hygroscopicity. Equilibrium hygroscopicity relates to 
the total amount of moisture adsorbed by a compound if 
allowed to equilibrate at a specific relative humidity 
(RH), whereas dynamic hygroscopicity refers to the rate 
at which a compound tends to sorb moisture from its 
surroundings (Umprayn and Mendes, 1987).
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The study of the hygroscopic nature of a solid drug is 
an essential part of every preformulation investigation, 
as solids containing residual water exhibit significant 
changes in many physicochemical properties relative to 
their dry state. These properties include chemical 
stability, crystal structure, powder flow, 
compactability, lubricity, dissolution rate and polymer 
film permeability (Zografi, 1988). Specifically in the 
case of chemical stability, moisture is considered to be 
the most deleterious environmental factor (Monkhouse, 
1984). This is exemplified by numerous reports of the 
detrimental effect of moisture on the chemical stability 
of drugs (Okamura et al. 1980; Yoshioka et al. 1979; Lee 
et al. 1965; Hasegawa et al. 1975; Carstensen et al.
1969).
A solid can be classified according to its
hygroscopicity by determining the critical relative 
humidity (i.e. the RH below which moisture adsorption 
does not occur) or the hygroscopic point (i.e. the RH at 
which the solid can take up 1% water in 24 hours) 
(Umprayn and Mendes, 1987). Callahan et al. (1986) have 
proposed an alternative classification which recognises 
4 degrees of hygroscopicity:
Class 1 . Non hygroscopic: Essentially no moisture 
increases occur below 90% RH. The increase in 
moisture content after storage for one week above 
90% RH is less than 20%.
Class 2 . Slightly hygroscopic: Essentially no
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moisture increases occur below 80% RH. The increase
in moisture content after storage for one week 
above 80% RH is less than 40%.
Class 3 . Moderately hygroscopic: Moisture content 
does not increase, more than 5% after storage at 
relative humidities below 60%. The increase in 
moisture content after storage for one week above 
80% R.H. is less than 50%.
Class 4 . Very hygroscopic: moisture content 
increases may occur at relative humidities as low 
as 40%. The increase in moisture content after 
storage for one week above 90% RH may exceed 30%.
An indication of a drugs equilibrium hygroscopicity is 
also given by the moisture adsorption isotherm. An 
adsorption isotherm not only yields information about 
the total amount of moisture taken up by the drug if 
allowed to equilibrate at various RH's, but also often 
provides an indication of the mechanism of moisture 
uptake and how the moisture is accommodated within the 
solid.
Generally water is adsorbed onto solid surfaces by 
physical- or van der Waals adsorption. Experimentally 
obtained physical adsorption isotherms can be grouped 
into 5 categories (Figure 3.14) (Glasstone and 
Lewis,l976). Type I isotherms are observed when a 
tightly held unimolecular layer of adsorbate is formed. 
Once all "active" sites on the solid surface have been 
covered, a limit in adsorption is reached. This type of
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isotherm is also observed for chemisorption. For Types 
II and III the formation of several layers of adsorbate 
has been postulated. In Type II adsorption, additional 
layers of water are adsorbed once the tightly held 
monolayer has been formed (indicated by the point of 
inflection). This occurs in nonporous amorphous or 
partially amorphous solids, eg. starch and cellulose 
(Zografi and Kontny,1986, Zografi et al.1984).
Figure 3.14 The five types of physical adsorption
isotherms
Type III adsorption tends to occur in crystalline, 
nonporous solids (Umprayn and Mendes, 1987), eg aspirin 
(Mitrevej and Hollenbeck, 1983). Type IV and V 
adsorption isotherms are characteristic of porous 
solids. In Type IV adsorption a monolayer is initially 
formed (indicated by the first point of inflection) 
followed by continued multilayer adsorption and 
condensation in the capillaries and pores (indicated by 
the second point of inflection).
Type I,II and III isotherms can be described by the BET 
(Brumauer, Emmet and Teller) equation (Glasstone and
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Lewis,1976). This equation is based on the assumption 
that water associated with a solid exists in two 
thermodynamic states. These are: tightly bound water 
(monolayer water which is not available for chemical 
interaction and surface dissolution) and solvent-like, 
"free" water (bulk water which is readily available for 
dissolution of the solid and for chemical reactions) 
(Zografi,1988; Monkhouse,1984). An extension of this 
concept is the GAB (Guggenheim, Anderson and de Boer) 
equation which proposes a third thermodynamic state of 
water, namely intermediate, loosely bound water 
(Zografi,1988):
WmCbk
W=- P O
(l- k - £ ~ )  (i-ic-P + C b k - 2 ~ )  
p o  p o  p o
Where W is the weight of water adsorbed per unit weight 
of dry solid at relative pressure p/po, Wm is the weight 
of water adsorbed corresponding to monolayer coverage 
and cb and k are equilibrium constants. Compared to the 
BET equation, this equation has been found to produce a 
superior fit for Type II adsorption isotherms (Zografi 
and Kontny, 1986; Zografi et al.1984).
The concept of rigidly categorising adsorbed water into 
several thermodynamic states, with bound water having 
little effect on the chemical degradation or physical 
properties of the solid has recently been challenged by
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Ahlneck and Zografi (1990). These authors have noted 
that the degree and strength of hydrogen bonding between 
tightly held water and the solid is variable (also 
Zografi, 1988) and can lead to "bound" water being quite 
mobile within the solid system. They have also pointed 
out that in many cases small amounts of adsorbed 
moisture (insufficient for multilayer formation) are 
able to promote chemical degradation and physical 
changes within the solid. This would not be possible if 
only bulk water were capable of causing physical and 
chemical changes. Instead it is proposed, (based on 
experimental evidence), that adsorbed water acts 
primarily as a plasticizer by preferentially dissolving 
into regions of molecular disorder (eg crystal defects, 
imperfections and amorphous regions). Molecules in 
regions of disorder are in an activated state because of 
increased molecular mobility and because more reactive 
chemical groups are exposed. This accounts for the 
greater ability to take up water. Once sufficient water 
is taken up, the system becomes plasticized. The 
resulting increased molecular mobility may then lead to 
greater chemical reactivity and to physical processes 
such as recrystallization.
The presence of water also appears to be highly 
detrimental to the stability of most vitamins. This 
manifests itself in the numerous stability problems 
experienced with liquid formulations (Buhler, 1988). To 
investigate the effect of atmospheric moisture on PL HC1
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the equilibrium hygroscopicity of PL HC1 was studied. A 
complete moisture adsorption isotherm was derived. 
Simultaneously physical changes were monitored with the 
aid of SEM and thermal analysis. The influence of 
atmospheric moisture on chemical stability is discussed 
in chapter 5.
3.3.4.2 METHODOLOGY
3.3.4.2.1 MATERIALS AND EQUIPMENT
Pyridoxal HC1 was obtained from Fluka AG (Buchs). Sodium 
dichromate, sodium chloride and phosphorus pentoxide 
were obtained from SAR chem (Krugersdorp). Lithium 
chloride, potassium acetate, magnesium chloride, sodium 
bromide, copper chloride, lithium sulfate and potassium 
sulfate were obtained from E Merck, (Darmstadt). All 
materials were analytical grade. Double distilled water 
(Milli Q system, Millipore, Bedford M.A.) was used 
throughout. Moisture determinations were made with a 
Mettler (Greifensee) DL18 Karl Fischer Titrator. DSC was 
carried out on a Mettler (Greifense) TA 3000 system 
(DSC20 cell) with hermetically sealed standard aluminium 
pans. TGA was carried out on a Du Pont TG 9900 system 
with open platinum pans. A Jeol (Tokyo) JSM 840 scanning 
electron microscope was used to observe and study 
surface characteristics and morphology of the particles. 
Saturated salt solutions were kept at constant
temperature in a Memmert (Schwarzbach) constant
temperature cabinet.
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3.3.4.2.2 PROCEDURE
PL HC1 was dried at reduced pressure over phosphorus 
pentoxide for 24 hours. Nine different controlled 
humidity environments were obtained by equilibrating 
various saturated salt solutions at 25°C. The salt 
solutions and humidities reported by Nyquist (1983) were 
used for this purpose (Table 3.3). Where possible salt 
solutions were selected that showed little variation in 
humidity with temperature changes. The solutions used 
have been reported to maintain constant humidity for 
five years.
Table 3.3 Relative humidities produced by the 
saturated salt solutions used. Mean values with standard 
errors (n=10)
Salt
20
Temperature °C 
25 30
LiCl 11.3 (0.065) 11.3 (0.104) 11.3 (0.096)
CH3COOK 22.5 (0.192) 21.6 (0.095) 21.5 (0.192)
MgCl2 33.1 (0.198) 32.8 (0.086) 32.4 (0.253)
Na2Cr07 54.8 (0.093) 54.4 (0.165) 54.0 (0.120)
NaBr 59.5 (0.101) 57.5 (0.177) 56.0 (0.161)
CuCl2 67.7 (0.143) 68.0 (0.178) 69.0 (0.093)
NaCl 75.5 (0.089) 75.3 (0.062) 75.1 (0.134)
LiS04 88.2 (0.248) 87.8 (0.209) 87.5 (0.292)
k2S04 97.6 (0.430) . 97.3 (0.401) 97.0 (0.512)
Adapted from Nygvist,1983.
Approximately 200ml of each saturated solution with an 
excess of solid phase was placed in a 1 litre glass 
dessicator and allowed to equilibrate at 25°C for 48 
hours. Three dried samples of PL HC1 (approximately 
500mg) in open vials were then placed in each hygrostat 
for 12 days (pilot studies showed no significant 
difference in moisture content between samples
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equilibrated for 12 and 15 days). Percentage moisture 
content was then measured by Karl Fischer titration as 
described earlier (section 2.5). Thermal analysis and 
SEM was carried out as described previously (sections
2.6 and 3.3.2.2) on samples stored at 11% RH and 75% RH 
at 25°C and 40°C for two weeks.
3.3.4.3 RESULTS AND DISCUSSION
An examination of the equilibrium moisture contents 
(Table 3.4) shows that above 90% RH PL HCl is 
deliquescent. At 97.3% RH half the sample weight is 
contributed by water and the sample can be seen to be 
dissolving in the surrounding liquid. Another striking 
feature is the discontinuity in the adsorption isotherm 
(Figure 3.15) in the region of 60 - 68% RH.
Table 3.4 Results of moisture content determination.
Relative 
Humidity (%)
Average Moisture 
Content (n=3) (mg/g)
Standard
Error
11.3 1.9 0.0123
21.6 2.7 0.0039
32.8 2.9 0.0064
54.4 3.7 0.0056
57.5 3.9 0.0042
68.0 2.4 0.0053
75.3 9.3 0.0269
80.9 15.8 0.0249
97.3 517.2 0.3629
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100
Relative humidity (%)
Figure 3.15 Moisture adsorption isotherm for PL HC1 
(25°C) with confidence intervals (p>0.05, n=3)
Moisture isotherms of this nature have previously been 
reported for amorphous systems which transform into 
energetically more stable, less hygroscopic crystalline 
systems when exposed to moisture (Umprayn and Mendes, 
1987; Makower and Dye, 1956) (Figure 3.16).
Figure 3.16 Typical moisture adsorption isotherms of 
a) an amorphous system (eg sucrose) undergoing 
transition to a crystalline system, b) an amorphous or 
partially amorphous system and c) a crystalline system
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Although hygroscopicity is highly order dependant 
(Huttenrauch, 1977), even small changes in crystal 
structure can lead to significant differences in 
hygroscopicity. This has been exemplified by the marked 
differences in hygroscopicity of the polymorphs of
indomethacin (Imaizumi et____ ad, 1980) and
chlortetracycline (Miyazaki et al. 1974). It should be 
noted that metastable polymorphs have energetically 
unstable molecular arrangements and can therefore be 
regarded as activated systems relative to their stable 
form. Consequently metastable polymorphs can be expected 
to be more hygroscopic.
In the present study a moisture induced transition from 
the predominantly metastable state (II) to a more 
stable, less hygroscopic form is evident from DSC 
thermograms and electron micrographs of PL HC1 stored at 
75% RH (Figures 3.17, 3.18 and Table 3.5).
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Figure 3.17 DSC traces of PL HC1 a) as supplied; 
b) stored at 25°C, 11% RH; c)stored at 25°C, 75% RH; 
d) stored at 55°C, 11%RH and e) stored at 55°C, 75% RH.
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A marked change in the ratio of the endothermic peak 
areas (I and II) which correspond to the enthalpies of 
melting of the metastable form II and the stable form I 
is observed (see Figure 3.17 and Table 3.5).
Table 3.5 Peak temperatures (T,°C) and enthalpies ( H, 
J/G) of PL HC1 obtained from the DSC thermograms under 
various storage conditions
Sample Storage
Conditions
Peak
T
II
AH
Peak I 
T ta H
A Hn *  
A Hj-
a) No storage 170.3 87.8 185.0 91.2 0 . 9 6
b) 25 ° c , 11% RH,
14 days
171.7 81.6 184.6 88.1 0.93
c) 25 ° c , 75% RH, 
14 days
172.3 75.9 185.2 94.4 0.80
d) 40 °C, 11% RH, 
14 days
172.2 78.1 182.4 76.6 1.01
e) 40 °C, 75% RH, 
14 days
172.3 72.1 187.3 91.2 0.79
The ratio of the enthalpies of melting corresponding to the 
two endothermic peak areas (I and II).
The decrease in the melting peak of the metastable form 
suggests a partial conversion to the stable polymorph.
This correlates well with the observed moisture sorption 
isotherm (Figure 3.15) and the scanning electron 
micrographs , where partial conversion to thin, platy
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crystals with large faces and well defined edges is 
evident at 75% RH (Figure 3.18).
a)
Figure 3.18 Scanning electron micrographs of a) PL HC1 
as supplied (x 900 and x 2700 magnifications 
respectively) and b) PL HC1 stored at 75% RH (x 900 and 
x 2700 magnifications respectively).
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3.3.4.4 CONCLUSION
PL HC1 appears to be physically unstable at elevated 
levels of atmospheric moisture. The moisture adsorption 
isotherm and the thermal analysis indicate that in the 
region of 57-68% RH, PL undergoes a partial polymorphic 
transition resulting in a sudden decrease in its 
moisture adsorption capacity. This possibly occurs 
according to the mechanism of moisture sorption recently 
proposed by Ahlneck and Zografi (1990), where water is 
predominantely adsorbed into the metastable regions of 
the solid. Once sufficient water has been adsorbed, the 
system is plasticized. The resulting increased molecular 
mobility may then facilitate the conversion to a more 
stable molecular arrangement.
PL HC1 is also a deliquescent solid and adsorbs large 
quantities of water above 70-75% RH. The increase in 
freely available water would be expected to 
significantly contribute to the decomposition of the 
solid (this is dicussed in detail in chapter 5).
In conclusion, there are strong indications that a 
polymorphic transformation to a stable, less hygroscopic 
form of PL HC1 can be induced by exposure of the 
substance to elevated moisture levels. This stable 
polymorphic form of PL HCl is of interest as its lower 
hygroscopicity may enhance chemical stability, while the 
concurrent expected decrease in solubility is unlikely 
to be significant as PL HCL is a highly water soluble
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substance. Furthermore it is apparent that precautions 
must be taken to protect PL HC1 from the deleterious 
effects of moisture during manufacture and storage. 
Products containing PL HC1 should be stored in air tight 
containers and a dessicant should be included.
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CHAPTER FOUR
4 SOLUBILITY ANALYSIS
4.1 INTRODUCTION
The extent of absorption and bioavailability of a drug 
administered orally as a solid dosage form is strongly 
influenced by its solubility characteristics. This can 
be seen from the schematic representation of the 
processes involved in drug release and absorption in the 
gastrointestinal tract (GIT) (Figure 4.1).
A b
Intact Ta b le t--------------------------------* Granules------------------------------- * Primary Drug Particles
Figure 4.1 Disintegration (A, B) and dissolution 
processes (k17 k 2 , k3 ) that precede drug 
absorption after administration of a 
tablet (Gibaldi, 1984).
The dissolution of the drug in the aqueous fluids of the 
GIT is a central and possibly rate limiting step in 
absorption. Important parameters characterizing the 
aqueous solubility are the equilibrium solubility, the 
intrinsic dissolution rate and the ionization constants 
of the drug.
Gastrointestinal Fluids
K
Drug Absorbed 
in Body
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Once in solution, the drug is available for absorption. 
At this point the relationship between the lipid 
solubility of the drug, its tendency to ionize and pH of 
the absorption site becomes critical. This relationship 
is the basis for the pH-partition theory of drug 
absorption (Gibaldi, 1980). The theory assumes that the 
cell membranes of the GIT present a simple lipoidal 
barrier to the transport of drugs. Thus, non-ionized 
acidic and basic drugs, if sufficiently lipophilic, 
would be absorbed. In contrast, the ionized forms would 
remain largely unabsorbed. Therefore, the larger the 
non-ionized fraction of a drug, the better its 
absorption. The extent of ionization of a drug in 
solution depends on the ionization constant (ka) and the 
pH of the solution and can easily be calculated by the 
Henderson-Hasselbach equation.
However, the pH-partition theory fails to recognize the 
importance of the surface area of the absorption site, 
the retention time at the absorption site and the fact 
that organic ions can be absorbed slowly from the GIT. 
It is therefore not a universal theory of drug 
absorption (Gibaldi, 1984).
Nevertheless, in many instances the lipophilicity 
(measured as a partition coefficient) and the ionization 
constants considered together with the aqueous 
solubility of a drug provide a good base for predicting 
bioavailability problems (Nyqvist, 1986). Should such
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problems arise, then various methods for enhancing the 
inherent solubility for the drug can be considered. 
These include salt formation, prodrug development, 
micronization, crystal modifications, solid dispersions 
and the formation of cyclodextrin inclusion compounds 
(Gibaldi, 1984; Motola and Agharkar, 1984; Halebian, 
1975 and Duchene and Wouessid jewe, 1990). In this 
chapter the available solubility and ionization data for 
PL HC1 are reviewed. In addition, solubility
estimations are made and lastly the partition 
coefficient for PL HC1 is determined.
4.2 THE SOLUBILITY OF PYRIDOXAL HC1
4.2.1 INTRODUCTION
Solubility is a complex phenomenon and depends on the 
physicochemical properties of the solvent and solute as 
well as on the temperature, pressure, agitation speed 
and pH of the solution. Quantitatively solubility can 
be defined as the concentration of solute found in a 
saturated solution at a certain temperature. This can 
be expressed in various ways eg. mass/volume, molality, 
molarity or as a percentage. For substances whose 
solubilities are not exactly known, the terms given in 
Table 4.1 can be used.
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T a b l e  4.1 T e r m s  of a p p r o x i m a t e  s o l u b i l i t y
Term Parts of solvent
required
per part of solute
very soluble less than 1 part
freely soluble 1 to 10 parts
soluble 10 to 30 parts
sparingly soluble 30 to 100 parts
slightly soluble 100 to 1000 parts
very slightly soluble 1000 to 10000 parts
practicly insoluble more than 10000 parts
(Adapted from Martin et al. 1983)
The solubility of solids in liquids is as yet incompletely 
understood and can therefore not be satisfactorily predicted 
except for ideal solutions (Martin et al. 1983).
4.2.2 METHODOLOGY
For most organic solvents there is no documented solubility data 
concerning PL HC1. A semi-quantitative procedure was therefore 
used to estimate the solubility of PL HC1 in various organic 
solvents according to Table 4.1.
4.2.2.1 MATERIALS AND EQUIPMENT
The following analytical grade materials were used: 
2-propanol (E Merck, Darmstadt), acetone (BDH, Poole), 
chloroform (BDH, Poole), ether (E Merck, Darmstadt), 
acetonitrile (Carlo Erba, Milan), tetrahydrofuran (E 
Merck, Darmstadt) and PL HC1 (Fluka, Buchs). Solutions 
were stored in a temperature controlled oven (Memmert, 
Schwabach).
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4.2.2.2 PROCEDURE
lOOpl of organic solvent was added to a test tube 
containing lOmg PL HCL. The tube was sealed, 
periodically shaken and stored for 24 hours at 25°C. If 
complete solubilization occurred, then PL HC1 was judged 
"soluble" in that particular solvent (in accordance with 
Table 4.1). If undissolved solute was still visible, 
the volume of the solution was increased in multiples of 
ten and the procedure was repeated.
4.2.3 RESULTS
The experimentally determined solubility estimates and 
the literature solubility data are presented in table 
4 . 2 .
Table 4.2 The solubility of pyridoxal hydrochloride
solvent solubility of PL HCL reference
(25 C)
water 50g /100ml Budavari et_al,1983
ethanol 1.7g/100ml Budavari et al.1983
propanol sparingly soluble *
acetone slightly soluble *
chloroform very slightly soluble/insoluble *
ether very slightly soluble/insoluble *
acetonitrile very slightly soluble/insoluble *
tetrahydrofuran very slightly soluble/insoluble *
* Determined experimentally.
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4.2.4 DISCUSSION AND CONCLUSION
PL HC1 is freely soluble in aqueous solution and 
relatively soluble in aliphatic alcohols. However, 
solubility rapidly declines with decreasing polarity of 
the solvent. As a result PL HC1 is relatively poorly 
soluble in most organic solvents. It has been suggested 
(Wells, 1988) that absorption problems may occur in 
compounds with aqueous solubilities which are lower than 
lOmg/ml (pH 1 - 7; 37°C). As PL HC1 substantially 
exceeds this limit (500mg/ml, 25°C) , it is unlikely that 
aqueous solubility will limit the rate of absorption.
4.3 THE IONIZATION CONSTANTS OF PYRIDOXAL HC1
4.3.1 INTRODUCTION
Most drugs, including PL HCl, are either weak acids or 
bases. When dissolved in water, these drugs will ionize 
to some extent and an equilibrium is reached between 
the ionized and non-ionized forms of the drug. For a 
weak acid (HA) this can be described as follows:
HA + H20 ---»• H 30+ + A"
Assuming that water is in excess and that its
concentration remains constant during the reaction, the
following rate equation can be applied:
K  = IH3QILLAU 
[HA]
The rate constant, ka, is known as the ionization,
dissociation or acidity constant. 
Similarly, for a weak base:
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k b =  r o H - i  r b h * i
[BOH]
where kb is the basicity constant. However, kb is seldom 
used. Instead, the Ka values of the conjugate acids are 
usually employed in calculations involving ionization 
constants.
As previously discussed (section 4.1), the ka values 
are important as they determine the extent of drug 
ionization at a specific pH. This in turn influences 
the partitioning of the drug between the lipid membranes
and the aqueous fluids of the GIT. Furthermore
values also provide information concerning the
dependence of drug solubility on the pH of the
surrounding environment (Motola and Agharkar, 1984). 
The relationship between the aqueous solubility of an 
acidic drug and pH is defined by a modified version of 
the Henderson-Hasselbach equation:
pH = pka + looTCsJ 
' [Ca]
where Cs and Ca refer to the molar concentrations of the 
salt and free acid respectively.
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4.3.2 THE MACROSCOPIC IONIZATION CONSTANTS OF PL HCL
IN SOLUTION.
PL has three ionizable groups. In the case of the free 
aldehyde these are the pyridine group, the 3-hydroxy 
group and the 5-methyl hydroxy group. Furthermore in 
aqueous solution PL exists in three different molecular 
arrangements (Figure 4.2).
Figure 4.2 The various molecular structures of PL in 
aqueous solution, a) PL aldehyde? b) PL hemiacetal and 
c ) PL hydrate.
This is due to the inherent instability of the 4-formyl 
group. In solution pyridine aldehydes show a marked 
tendency towards hydration, forming covalent hydrates of 
the general form RCH(0H)2 (Kortnyk and Singh, 1963; 
Heinert and Martell, 1959). In addition, the free 
aldehyde group also readily interacts with the 5-hydroxy 
methyl group to form an internal hemiacetal (Nurnberg, 
1961; Kortnyk and Singh, 1963; Morosov, 1986; and 
Metzler and Snell, 1955). Indeed, in acidic and neutral 
solutions pyridoxal exists almost exclusively as the 
hemiacetal (approximately 98.5% - 99.5% ) with the free 
aldehyde and its hydrate only becoming significant at pH 
10 - 11 (Harris et al. 1976; Morosov, 1986; and Kortnyk
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and Singh, 1963). For our purposes the electronic state 
of pyridoxal need only be considered for the 
physiological pH range (2 - 7.4). The influence of the 
free aldehyde and its hydrate on the ionic eguilibria is 
therefore negligible.
Given the three ionizable groups, PL can thus exist in 
five electronic states in solution (Figure 4.3).
Neutral form
◄----------- K ,----------- ► ◄-------- K2----------► <----------- K3-------------►
(pK-| =  4.21) (pK2 =  8.68) (pK3 =  13.0)
pKa =  4.94 
pKb =  4.30 
pKc = 8.52 
pKd =  8.2 
Kz =  0.64
Figure 4.3 Simplified diagram of ionic equilibria of 
PL
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The macroscopic ionization constants of PL (klf k 2 and 
k3) have been the subject of numerous detailed studies 
and have been determined spectrophotometrically, 
spectrofluorometrically and titrimetrically (Metzler and 
Snell, 1955 ; Bridges et al. 1966 ; Morosov et al. 1967 
and Harris et alf 1976). These ionization constants are 
summarized in Table 4.3 .
T a b l e  4 . 3  M a c r o s c o p i c  i o n i z a t i o n  c o n s t a n t s  f o r  P L
pk, p k 2 p k 3 R e f e r e n c e
4.20 8.66 13.0 (Metzler and Snell, 1955)
4.23 8 .59 (Harris et al, 1976)
3.93 8.62 (Morosov et al, 1967)
3.9 8 .9 (Bridaes et al. 1966)
Due to the tautomeric relationship between the dipolar 
ion and the non-ionized form of PL (Figure 4.4), it is 
not possible to assign the pkA and pk 2 values to 
particular ionizable groups as they involve both 
pyridinium and 3-hydroxy groups. It is also clear that 
PL can never exist in the fully non-ionized form in 
solution, as a certain proportion of PL (dependent on 
the tautomeric constant, k2) will always be present as 
the dipolar ion.
4.3.3 CALCULATION OF THE MICROSCOPIC IONIZATION 
CONSTANTS
It is apparent that the pk2 and pk2 can not be used to 
calculate the proportions of the various ionic species
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present at a specific pH. For this purpose the ratio 
(kz) of dipolar ion to the non-ionized form has to be 
known. The macroscopic ionization constants (pklf pk2 
and pk3) are related to the ionization constants for the 
individual ionizable groups, (i.e. microscopic constants 
pka, pkb, pkc and pkd) and the tautomeric ratio (k2) as 
follows (Metzler and Snell, 1955) :
ki = ka + kb ........ A
1 = 1 + 1 ..... B
k2 kc kd
kz = ka = kc ........ C
kb kd
Thus if pkw  pk2 and one other constant are known, all 
other constants can be determined. For pk3 and pk2 the 
values determined by Metzler and Snell (1955) were used. 
The value for pka corresponding to 4.94 was obtained from 
the literature (Likos and Kishore, 1986). Substituting 
these values into equations A, B and C the following 
results were obtained:
Table 4.4 Microscopic ionization constants and the 
tautomeric constant for PL
pka = 4.94
pkb = 4.30
pkc = 8.52
pkd = 8.20
k2 = 0.64
The proportions of the various ionic species present in 
solution at pH 5.5 and 7.4 were then calculated by 
applying the Henderson-Hasselbach equation (Appendix III)
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Table 4.5 Proportions of ionic species present in 
solution at pH 5. and 7.4
Ionic Species Cation Neutral Dipolar Anionic
% at pH 5.5 
% at pH 7.4
4.88%
0.065%
57.96% 
57.89%
37.1%
37.1%
0.06% 
4.98%
4.3.4 DISCUSSION AND CONCLUSION
In solution PL exists in various molecular arrangements, 
of which PL hemi-acetal is the dominant form. PL hemi- 
acetal itself exists as a series of ionic and tautomeric 
equilibria. As a result of the tautomeric relationship 
between the non-ionized molecule and the dipolar ion, PL 
is never 100% non- ionized. PL is mainly absorbed in 
the small intestine by passive diffusion (Buss et al. 
1980). The proximal small intestine has a pH of 
approximately 5.5 . Under these conditions 58% of a
dose of PL can be expected to be non-ionized, whereas 
37% will occur as the dipolar ion. An increase in 
alkalinity to pH 7.4 does not significantly affect the 
extent of ionization. Ionization in the GIT fluids is 
therefore not expected to impede the absorption of PL to 
a great extent.
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4.4 DETERMINATION OF THE PARTITION COEFFICIENT FOR 
PL HC1
4.4.1 BACKGROUND
If a solute is added to a system of two immiscible 
phases, then the solute distributes itself between the 
two phases so that, at equilibrium and constant 
temperature, the ratio of the solute concentrations in 
the two phases has a definite constant value which is 
independent of the actual amount dissolved (Glasstone 
and Lewis, 1976). This ratio is known as the
distribution ratio or the partition coefficient (P).
For pharmaceuticals P is usually determined in 
water/non-polar organic systems. These can serve as 
model systems for drug transportation from aqueous 
fluids across lipid membranes during absorption and 
transportation to the site of action. Octanol is often 
chosen as the organic phase as it is weakly polar and 
can contain a significant amount of water in the form of 
hydrogen bonded complexes. To an extent this serves as 
a model for the complex lipid membranes which are mainly 
hydrophobic but also have hydrophilic regions containing 
bound water molecules (Smith et al. 1975). Other
organic solvents that can be used include chloroform, 
ether and cyclohexane.
P may therefore provide an indication of a drugs
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pharmacokinetic properties and biological activity. In 
particular, values of log P have been well correlated 
with specific pharmacokinetic properties and biological 
activity (eg. therapeutic effect, toxicity and 
pesticidal activity) in structure activity studies (Chou 
and Jurs, 1980) .
Mathematically P can be represented as follows:
P = Ce 
Cw
where P, CQ and C„ refer to the partition coefficient, 
the drug concentration in the organic phase and the drug 
concentration in the water phase respectively. It is 
assumed that the drug is fully non-ionized under the 
conditions of measurement. If the measurements are 
carried out at a pH such that the drug is partially 
ionized, then the ratio determined is the apparent 
partition coefficient (Papp). P is related to Papp by the 
following equation:
P«pp = P • fu
where fu is the fraction of non-ionized drug present 
(Pharmaceutical Codex, 1979).
It is apparent that as an indicator of drug transport 
across physiological barriers P is a valuable parameter 
for the formulation pharmacist. As no literature values 
of P or log P could be found for PL, it was decided to 
determine Papp for PL HC1 at pH 7.4 in a water/octanol 
system. An estimate of the true P value was then
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obtained by calculation.
4.4.2 METHODOLOGY
4.4.2.1 MATERIALS AND APPARATUS
PL HC1 (Fluka AG, Buchs), 4-amino antipyrine (Fluka AG, 
Buchs), ammonium persulphate (BDH, Poole), sodium 
hydroxide (Merck, Darmstadt), hydrochloric acid (BDH, 
Poole) and 1-octanol (SAR Chem, Krugersdorp) were used 
in the study. All materials were of analytical grade 
quality. Double distilled water (Milli Q System, 
Millipore, Bedford M .A .) was used. Partitioning was 
carried out in a 200ml glass separating funnel with lid. 
A Phillips/Pye Unicam (Cambridge) PU8700 UV/VIS 
spectrophotometer with 1 cm quartz cells was used for 
absorbance measurements.
4.4.2.2 PROCEDURE
P was determined by using the "shake flask" method. 
Approximately 200ml 1-octanol and phosphate buffer (pH 
7.4, BP 1990), were added together and pre-equilibrated 
overnight at 25°C. This was done to fully saturate the 
octanol with water and vice versa. Approximately lOmg 
PL HCl, accurately weighed, was dissolved in 50ml 
presaturated phosphate buffer. The buffer solution and 
50ml presaturated 1-octanol were then mixed together in 
the glass separating funnel by inverting the funnel 100 
times. The funnel was then allowed to stand at 25°C for 
30 minutes. Aqueous phase (10 ml) was then drawn off
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and adjusted to pH 2.1 with dilute HC1. The PL
concentrations of 3 individual 1ml samples were then
determined spetrophotometrically as previously described 
(section 2.2.2). The whole procedure was repeated 3 
times. The Papp was calculated by difference, ie.
Papp J C_T -  CH 
C„
Where CT is the total PL concentration in both the 
aqueous and oil phase and CH is the PL concentration in 
the aqueous buffer phase. The true partition
coefficient, P, was calculated using the previously 
described relationship between Papp and P (section 4.4.1):
P
4.4.3 RESULTS
A linear calibration curve (r=0.9998) was obtained over 
the concentration range of 15mg/l-25mg/l. Linear 
regression yielded the following equation:
Absorbance = 0.0125 PL concentration - 0.0083. Papp was 
determined as the average of 3 separate experiments. 
These are summarized in Table 4.6. A mean value of 0.44 
(standard error (s*) = 0.0 27) was determined for Papp with 
a confidence interval of 0.38 - 0.49 (p > 0.1). A value 
of 0.76 (log P = -0.119) was calculated for the true 
partition coefficient, P.
101
Table 4.6 Determination of Papp
Experiment CT
(mg/1)
cw
(mg/1)
Mean Cw 
(mg/1)
s?
(%)
Papp
A 20.1 13.9 
13.8 
13.7
13.8 0.72 0.46
B 20.2 13.7
13.5
13.5
13.6 0.85 0.48
C 21.6 15.5
15.5 
15.4
15.5 0.37 0.39
4.4.4 DISCUSSION AND CONCLUSION
Although Papp is a more realistic measure of partition in 
the body, P was determined to allow a comparison with 
the P values of other drugs. Compared with known log P 
values (Table 4.7), it can be seen that log P for PL is 
low ( -0.119 ).
Table 4.7 Partition coefficients of various compounds 
(in octanol/water systems)
substance logP
Ethanol -1.00
propanol -0.46
n-butanol -0.18
thymol 2.98
sotalol 0.24
labetalol 3.09
propranolol 3.37
pindolol 1.75
timolol 1.98
atenolol 0.16
metoprolol 1.80
chlorpromazine 5.41
fluphenazine 5.67
thioridazine 6.51
alimemazine 5.01
perphenazine 5.28
(Martin et al. 1983 :Buraot et__al,1990;Burgot and
Burgot,1990)
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However, the negative effect which the poor 
lipophilicity may have on absorption is counteracted by 
the excellent solubility of PL in the aqueous GIT 
fluids. Furthermore the small intestine, the principal 
site of absorption, provides a large surface area for 
absorption. Lastly, studies conducted on PN, which is 
also poorly soluble in non-polar solvents, show that 
single doses of up to 1000 mg are completely absorbed 
(Bauernfeind and Miller, 1978). Accordingly, 
bioavailability problems are unlikely to occur if PL HCl 
is administered in a solid dosage form.
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CHAPTER 5
5 CHEMICAL STABILITY ANALYSIS OF PYRIDOXAL HC1
5.1 INTRODUCTION
The bulk of the research work on the stability of PL HC1 
has focused on the stability of PL HC1 in aqueous 
solution. One of the first comparative stability studies 
of PN, PL and PM was carried out by Cunningham and Snell 
(1945). These workers found that compared to the other 
two vitamers PN had superior stability characteristics. 
In neutral and alkaline solution PL was found to be 
rapidly inactivated when exposed to light. When heated 
to 100°C in HCl and H2S04, PL was found to be stable. 
However, decomposition occurred in alkaline conditions. 
A more recent study on the photosensitivity of vitamin 
B6 found that when exposed to normal laboratory light, PL 
was stable for up to eight hours at pH 4.5. However, at 
pH 6 only 55% of the initial PL HCl was recovered (Ang, 
1979). In a further study Morosov (1986) also observed 
the formation of 4-pyridoxic acid and its lactone when 
PL solutions were irradiated in the presence of oxygen. 
Saidi and Warthesen (1983) studied the influence of pH
on the kinetics of vitamin B6 degradation in solution. 
They also studied vitamin Bs photolysis in dry food 
systems. It was found that at 40°C and 60°C PL solutions 
decomposed most rapidly at pH 5-6. The solutions were 
most stable at low pH. Decomposition was temperature 
dependent and appeared to follow first order kinetics. 
The major degradation product was 4-pyridoxic acid. PL 
HC1 was found to be extremely light sensitive in the 
solid state. At 28°C, 32% RH and 400 ft-c light intensity 
PL HC1 incorporated in a model food system had a half 
life of 6.4 days. This was increased to 10.3 days at 200 
ft-c. Degradation followed apparent first order 
kinetics. Gregory and Kirk (1978) also assessed the 
stability of vitamin B6 in solid state model food 
systems. First order kinetics were observed for the 
degradation of PL at 37°C, 60% RH.
The stability characteristics of PL HC1 in solution and 
the destabilizing effects of light and neutral and 
alkaline conditions have been well documented. The 
remainder of this chapter therefore focuses on the solid 
state stability of PL HCL. Initially the effect of 
moisture and temperature on the stability of solid PL 
HC1 on its own is investigated. In the second part of 
this chapter the compatibility of PL HC1 with several 
common tablet and capsule excipients is studied.
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5.2 THE SOLID STATE STABILITY OF UNFORMULATED PYRIDOXAL
HC1
5.2.1 CAUSES AND MECHANISMS OF DEGRADATION IN SOLID 
STATE PHARMACEUTICAL SYSTEMS
Pharmaceutical systems are generally characterized by a 
low level of entropy, this will often favour 
degradation. The underlying cause of the instability of 
most pharmaceutical systems is therefore of
thermodynamic origin (Rhodes, 1984). Instability in 
drugs can be caused by physical, chemical or biological 
mechanisms. Instability in pharmaceutical systems can 
have the following consequences:
i) loss of active drug; ii) loss of vehicle; iii) loss 
of content uniformity; iv) reduction of bioavail­
ability due to decreased solubility; v) impairment of 
pharmaceutical elegance, eg. discolouration and
development of distasteful flavours; vi) production of 
potentially toxic materials (Rhodes, 1984). For tablet 
systems biological degradation is unlikely to be of 
major importance. The high temperatures and pressures 
reached during compression tend to inactivate harmful 
microbes (Fassihi and Parker, 1987). Selected aspects of 
physical stability have been discussed in chapter 3.
In contrast to chemical decomposition in solution, the 
chemical mechanisms of solid state decomposition are 
complex and often only partially understood (Connors gt 
al. 1986a). Various reaction orders are possible,
106
depending on the mechanism involved. Degradation may 
occur via various competing or sequential reactions. The 
complexity of solid state decomposition reactions is 
also illustrated by the sigmoidal reaction rate curves 
observed by many workers (Figure 5.1). The curve can be 
divided into three stages: an induction period, an 
acceleration period and a decay period.
Figure 5.1 Typical sigmoidal decomposition curve
a) induction period; b) acceleration period; c) decay
period
This type of decomposition curve can be explained by the 
Prout-Tompkins model of solid state decomposition 
(Carstensen, 1974). A refined model was later put 
forward by Jacobs and Tompkins (Ng, 1975). The model 
assumes that decomposition is governed by the formation 
and growth of reaction nuclei or "hot spots" on the 
crystal surfaces. These centres of reactivity occur in 
disordered regions of the crystal, eg. crystal defect 
structures such as dislocations and stacking faults. 
Once decomposition products are formed these introduce 
additional strains on the crystal structure and promote 
the formation of new reaction nuclei. Such kinetics have
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been reported for the solid state decomposition of p- 
aminosalicylic acid (Kornblum and Sciarrone, 1964), 
acetyl salicylic acid and derivatives (Hasegawa et al. 
1975) and glutathione (Aruga et al. 1978).
Similar curves have also been observed for multi-phasic 
reactions. These reactions initially occur mainly in 
the solid state, however due to the formation of liquid 
decomposition product layers or the absorption of 
excessive amounts of water and deliquescence of the 
drug, later stages of the degradation process occur 
mainly in solution and follow first order solution 
kinetics. Such kinetics, also termed Bawn kinetics, have 
been observed for aminobenzoic acid which decomposes to 
liquid aniline and carbon dioxide (Carstensen, 1974). 
Sigmoidal decomposition curves have also been derived 
for propantheline bromide (a deliquescent drug) exposed 
to moist atmospheres (Yoshioka and Uchiyama, 1986; 
Carstensen et alf 1987).
An alternative mechanism for solid state drug 
degradation which has been suggested involves the 
concentrated suspension model. According to this model 
degradation primarily occurs in layers of drug saturated 
solutions surrounding the individual drug particles. The 
source of the solvent is critical. This may be a melt 
from a drug or excipient with low melting point, 
residual solvent from a wet granulation, adsorbed 
atmospheric moisture or a solvate which has released its
108
solvent (Connors et al. 1986b). The most common 
situation is probably that involving adsorbed 
atmospheric moisture. In contrast to the reaction nuclei 
model, moisture must be present in excess. Where only 
trace amounts of moisture are present a mechanism 
involving the penetration of water into energetic hot 
spots (regions of disorder), thus increasing molecular 
mobility and reactivity is more likely (Ahlneck and 
Zografi, 1989). The kinetics governing drug degradation 
in saturated aqueous layers have been elucidated by 
Leeson and Mattocks (1958). Leeson-Mattocks kinetics 
assume that decomposition can be totally accounted for 
by decomposition of the dissolved drug. The 
concentration of drug in solution is determined by the 
solubility of the drug and while solid drug remains 
available for dissolution, the model follows pseudo zero 
order kinetics analogous to those observed for drug 
degradation in suspension. The apparent zero order 
degradation rate constant being the product of the 
intrinsic first order degradation rate constant and the 
solubility of the drug in the solvent (Carstensen, 
1988 ) .
The complexity of solid state degradation often leads to 
limitations in solid state stability studies of new 
substances as not all the variables controlling solid 
state stability are known. In addition, degradation 
mechanisms and kinetics of the drug in its final dosage 
form usually differ from those of the drug in its pure
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form. However, at the preformulation stage determination 
of exact mechanisms and kinetics (although useful if 
available ) is not essential. The priority at this stage 
is the determination and knowledge of the effect of the 
major environmental factors affecting drug stability 
(Wadke et al. 1989; Monkhouse, 1984). Omnipresent 
environmental factors to which the drug will be exposed 
during its lifetime include heat, light, oxygen and 
water. In particular, moisture is thought to be the 
single most important destabilizing factor (Monkhouse, 
1984). Moisture has been found to be the major 
destabilizing factor for sulpyrine (Yoshioka et al. 
1979), doxylamine succinate (Van Tonder et al. 1991), 
moexipril (Gu et al. 1990), glutathion (Aruga et al. 
1978), p-aminosalicylic acid (Kornblum and Sciarrone, 
1964) and thiamine HC1 (Carstensen et al. 1969). 
Associated factors such as the pH of the 
microenvironment may further modify the effects of any 
of the previously mentioned factors (Monkhouse, 1984; 
Rhodes, 1984).
The destabilizing effect of light on PL HC1 has been 
well documented (section 5.1). The primary aim of this 
study was therefore to establish the effect of 
temperature and atmospheric moisture on the stability of 
solid PL HC1. The effects of acidic and basic additives 
and an antioxidant were also investigated. Degradation 
kinetics were not established.
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5.2.2 METHODOLOGY
5.2.2.1 MATERIALS AND EQUIPMENT
Analytical grade PL HC1 (Fluka Ag, Buchs), sodium 
bicarbonate (BDH, Poole) and ascorbic acid (Merck, 
Darmstadt) were used. Samples were stored in
thermostatically controlled ovens (Memmert, Schwabach) 
during isothermal stress testing. Silica gel HF 60 
chromatoplates (E Merck, Darmstadt) were used to detect 
decompositiion products by TLC. A Beckman System Gold - 
liquid chromatograph (San Ramon, CA) equipped with a 
programmable solvent delivery module (model 126) and a 
diode array detector (model 168) was used to analyse the 
samples by HPLC.
5.2.2.2 PROCEDURE
Samples of PL HC1 (approximately 10.0 mg) were 
accurately weighed into open glass vials. The samples 
were then placed into controlled humidity environments 
(0% RH, 11% RH, 54% RH) and stored at 25°C and 55°C 
respectively. The controlled humidity environments were 
created as previously described (section 3.3.4.2). A 0% 
RH was created by equilibrating phosphorous pentoxide in 
a glass dessicator. Samples containing sodium 
bicarbonate and ascorbic acid (approximately 10.0 mg) in 
addition to PL HC1 were also prepared. After 14 days 
storage time the samples were analysed for the remaining
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amount of PL HC1 by HPLC and TLC as described previously 
(sections 2.3.2 and 2.4.2). To avoid sampling errors the 
whole sample was used in each case. Furthermore each 
sample was analysed three times.
5.2.3 RESULTS AND DISCUSSION
Table 5.1 shows that both high levels of temperature and 
relative humidity cause substantial degradation of PL 
HC1 (for more detailed data refer to Appendix IVa). The 
combination of both high temperature and RH was found to 
be the most detrimental storage condition. The - 
destabilizing effects of temperature and humidity are 
significant at the 90% level of confidence as shown by 
the factorial design experiment in section 5.2.2.2 .
Table 5.1 The solid state stability of PL HCl
Sample Storage Condition % Remaining
1 0% RH, 25°C 100.3
2 11% RH, 25°C 98.4
3 54% RH, 25°C 98.3
4 0% RH, 55°C 97.6
5 11% RH, 55°C 96.7
6 54% RH, 55°C 95.4
7*1 54% RH, 55°C 69.2
8*2 54% RH, 5 5°C 89.3
*1 PL HCl + sodium bicarbonate 
*2 PL HCl + ascorbic acid
The results clearly show the destabilizing effect of 
sodium bicarbonate when compared to ascorbic acid. This 
correlates well with previously reported stability
112
studies which indicated that PL is relatively stable in 
acidic solutions while unstable in alkaline solutions 
(Cunningham and Snell, 1945; Saidi and Warthesen, 1983). 
It therefore seems that the alkaline sodium bicarbonate 
significantly alters the pH of the microenvironment, 
thereby accelerating chemical decomposition. It must 
however be noted that ascorbic acid also destabilizes PL 
HC1. The acidifying and antioxidant effects therefore 
seem to be overshadowed by a negative interaction 
between PL HC1 and ascorbic acid.
The decomposition of PL HC1 can be rationalized with the 
aid of the concentrated suspension model. PL HC1 is 
highly water soluble and adsorbs large amounts of 
moisture at elevated humidity levels (section 3.3.4). 
Considerable surface dissolution can therefore be 
expected, resulting in the formation of a weakly acidic 
layer of solution. In strong acidic solution (pH<2) PL 
exists almost exclusively in the hemiacetal form. 
However, in weaker acidic solutions PL hemiacetal is 
partially hydrolysed (up to 1.5%) and a small amount of 
free aldehyde is formed (see section 4.3.2). Free 
aldehydes are much more reactive and oxidize readily 
when compared to their respective hemiacetals (Morrison 
and Boyd, 1983). This would also account for the 
increased decomposition observed under alkaline 
conditions, where a considerably greater percentage of 
free aldehyde is formed.
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Figure 5.2 Proposed scheme for the solid state 
degradation of PL HC1
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Solid state decomposition of PL HC1 in the presence of 
atmospheric moisture is therefore likely to involve the 
partial hydrolysis of the PL hemiacetal and rapid 
oxidation of the resultant free aldehyde (Figure 5.2). 
As previously mentioned (section 2.4.3) decomposition 
products could not be identified by HPLC. However, TLC 
provides a slightly clearer picture of PL HC1 
decomposition. Samples exposed to high temperature and 
relative humidity show three distinct decomposition 
products (Figure 5.3) at Rf 0, 0.17 and 0.4 8 in addition 
to a trail of other decomposition products.
Figure 5.3 Photograph of a chromatoplate viewed at 256 
nm showing PL HC1 decomposition products. (1) PL HCl 
standard, (2) PL HCl sample exposed to 55°C, 7 5% RH for 
2 weeks, (3) decomposition product Rf 0.48, (4) 
decomposition product R* 0.17 and (5) decomposition 
products at R, 0.
The pathway of decomposition is likely to involve 4- 
pyridoxic acid. This would then be partially converted 
to 4-pyridoxic acid lactone in the prevailing acidic
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conditions. Both these substances have been identified 
as major decomposition products of PL (Saidi and 
Warthesen, 1983; Morosov, 1986). Simultaneously a 
limited amount of PL hemiacetal may also be broken down 
to 4-pyridoxic acid lactone by direct oxidation.
Degradation caused purely by heat in the absence of 
moisture (see sample 4, Table 5.1) can be attributed 
mainly to elemental oxygen and the increased reaction 
rates at higher temperatures. However even a relatively 
low increase in the humidity of the environment eg. 11% 
RH (sample 5, Table 5.1) results in an increase in 
decomposition. It appears that moisture causes 
decomposition of solid PL HCl by hydrolysis of the 
hemiacetal and by increasing the plasticity of the solid 
state system, thereby decreasing the energies of 
activation as suggested by Ahlneck and Zografi (1991).
5.3 EXCIPIENT COMPATIBILITY TESTING
5.3.1 INTRODUCTION
The formulation of a stable and effective dosage form 
requires careful selection of the excipients used to 
facilitate administration, promote consistent release 
and bioavailability of the drug, and protect it from 
degradation (Wells, 1988d). Although often regarded as 
"inert", pharmaceutical excipients can in fact readily 
interact with drugs (Monkhouse, 1984). This may occur in 
three different ways. The drug and excipient may react
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with each other. Alternatively the excipient may alter 
the microscopic pH of the immediate drug environment. 
Lastly, hygroscopic excipients may increase the amount 
of water available for decomposition in the system 
(Ahlneck and Alderborn, 1988; Connors et al. 1986a). The 
detection of solid-solid interactions between drugs and 
excipients during preformulation is therefore of great 
importance.
The four techniques which can be employed for drug- 
excipient compatibility screening are isothermal stress * 
testing utilizing chromatographic techniques (HPLC or 
TLC), thermal analysis using DTA (differential thermal 
analysis) or DSC, diffuse reflectance spectroscopy and 
assessment of discoloration after exposure to light 
stress (van Dooren, 1983; Carstens, 1974). However, from 
a review of the literature it appears that isothermal 
stress testing and thermal analysis are the methods of 
choice.
5.3.1.1 ISOTHERMAL STRESS TESTING: GENERAL BACKGROUND
In its simplest form isothermal stress testing involves 
the exposure of binary drug-excipient mixtures to 
elevated temperatures and moisture levels to accelerate 
drug ageing and drug-excipient interactions. Unstressed 
samples are used as controls. After a specific storage 
time (eg 2 weeks at 55°C) the samples can then be 
analysed by visual comparison as well as by
chromatography (Carstensen et al. 1964; Carstensen,
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1974). The main disadvantages of this method from a 
preformulation point of view are that it is relatively 
time consuming, reguires the use and availability of a 
stability indicating method (is therefore labour 
intensive) and consumes relatively large amounts of 
sample. The extent to which these studies can be 
accelerated by increasing temperature stress is limited 
because the risk of inducing physicochemical changes 
that do not occur at ambient temperature increases 
(Monkhouse, 1984). Many workers therefore use 
temperatures not exceeding 50-60°C for isothermal * 
excipient compatibility studies which require a minimum 
incubation period of 2-3 weeks (Gu et al. 1990; Nyqvist, 
1986; van Dooren, 1983; Boatman and Johnson, 1981; 
Carstensen, 1974). However, the technique can be refined 
by employing fractional factorial designs which allow a 
reduction in the number of individual experiments and 
the amount of drug consumed (Motola and Agharkar, 1982; 
Ahlneck and Waltersson, 1986).
5.3.1.2 APPLICATION OF FACTORIAL DESIGNS TO EXCIPIENT 
COMPATIBILITY TESTING
Factorial designs are experimental designs that 
simultaneously evaluate the effects of various factors 
(eg temperature, moisture and presence of certain 
excipients) at several levels (eg high and low 
temperature). Depending on the choice of design, the 
effects caused by interactions of the various factors 
can also be evaluated. Statistical techniques are then
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applied to test the significance of the calculated 
effects. Various factorial designs exist and choice of 
design depends largely on the particular application ie. 
the number of factors and levels, the type of factors 
and nature of the experiment, the maximum feasible 
number of individual experiments and whether interaction 
effects must be detected. A particularly useful 
factorial design for the evaluation of up to four 
components in a mixture experiment is the simplex 
lattice design (Huisman et al. 1984). Other well known 
factorial designs which are suitable for experiments 
involving up to 3 factors are the central composite, 
Box-Behnken, and full factorial designs (Mulholland, 
1988). Ahlneck and Waltersson (1986) have reported the 
use of a 23 full factorial design to evaluate the 
compatibility of aspirin with 3 excipients. However, in 
preformulation excipient compatibility screening usually 
10 or more excipients are evaluated. With such an 
increase in factors, the required number of experiments 
rapidly escalates, rendering these designs impractical 
and inconvenient. For such experimental situations 
Plackett-Burman designs are particularly suitable 
(Motola and Agharkar, 1984; Connors et al. 1986c)
The method of Plackett and Burman (1946) provides 
saturated fractional factorial designs that allow 
multifactorial experiments to be carried out with a 
minimum of trials without compromising accuracy (the 
individual combinations or mixtures tested within the
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multifactorial experiment are referred to as trials). 
The advantages of this method in preformulation design 
are therefore the following: i) Efficiency is increased. 
This is vital when considering the limited amount of 
time and drug available at the preformulation stage, 
ii) Each variable is screened at two levels, iii) Each 
variable is screened in the presence of all other 
variables under investigation, iv) A study of the effect 
of environmental factors (eg temperature, humidity) can 
easily be incorporated in the experiment, v) Studies are 
carried out in a well designed experiment, the results - 
of which can be supported with statistical significance 
(Motola and Agharkar, 1984).
The method also has some limitations: only main effects 
can be determined, ie. interactions between two or more 
variables can not be detected. However, these are 
generally not of major interest (Ahlneck and Waltersson, 
1986; Box et al. 1978). Furthermore the smallest design 
that can be derived is an eight trial experiment.
5.3.1.3 EXCIPIENT COMPATIBILITY SCREENING USING DSC
An alternative preformulation compatibility screening 
method makes use of DSC. This technique does not require 
long term storage of mixtures and subsequent 
chromatographic analysis and uses only a few milligrams 
of drug per individual experiment. Thermograms of the 
individual excipients and of the drug are obtained and 
compared to the thermograms of drug-excipient mixtures.
120
Guidelines for the interpretation of the thermograms 
have been given by Smith (1982) and van Dooren (1983). 
Generally the thermogram of the mixture should broadly 
reflect the same thermal features as the superimposed 
thermograms of the drug and excipient. Any gross 
differences such as the appearance of new peaks, the 
disappearance of peaks or massive shifts in peak 
temperature or size are taken as a sign of interaction.
The value of employing thermal analysis as a predictive 
preformulation compatibility screen was demonstrated by 
Jacobson and Reier (1969). These workers found good 
correlation between data generated by DTA and 
accelerated ageing tests for mixtures of stearic acid 
with sodium oxacillin monohydrate, sodium dicloxacillin 
monohydrate, potassium penicillin G and ampicillin 
trihydrate. A similar approach was used to assess the 
compatibility of four excipients with cephradine 
(Jacobson and Gibbs, 1973). Again the results obtained 
by DTA and conventional isothermal stress studies 
correlated well. However, apart from these studies many 
of the published DSC studies have not provided direct 
verification of the predictions they make. Only one 
other detailed study comparing the accuracy of chemical 
compatibility predictions made by DSC screening to those 
made by isothermal stress testing could be found. In 
this study the DSC technique was judged to be unreliable 
(Chrzanowski et al. 1986). However, these authors 
applied a modified DSC technique which relies on
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measuring differences in the heats of melting (EL- 
Shattaway et al. 1981). The study therefore does not
really evaluate the more generally accepted, qualitative 
approach to DSC compatibility screening, which relies on 
detecting large aberrations in the thermograms of the 
drug-excipient mixtures. However, other authors have 
also stated that results obtained by DSC screening are 
often not conclusive (Gordon et al. 1984; van Dooren, 
1983? Smith, 1982). Amongst the factors which have 
contributed to this observation are the high
temperatures and the rapid heating rates which may give - 
rise to degradation reactions that do not take place at 
room temperature. Furthermore the lack of moisture 
stress in DSC experiments may result in moisture 
mediated interactions being over looked. In addition, in 
various cases interpretation of thermograms becomes 
difficult. These include coincident thermal features (eg 
coincident melting), premature decomposition of one 
component (the interaction may then involve the 
degradation products), premature sublimation or
vapourization or the formation of a mixed melting point 
entity (physical interactions do not necessarily affect 
chemical stability) (van Dooren, 1983; Smith, 1982). 
These difficulties have led van Dooren (1983) to propose 
an experimental design in which DSC screening is 
supplemented by isothermal stress tests. However, this 
largely negates the advantages of DSC screening.
N o n e t h e l e s s  D S C  screening continues to b e  w i d e l y
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regarded as a major method for preformulation
compatibility testing (Wells, 1988d, Wadke et al. 1989) 
and compatibility studies utilizing DSC techniques 
continue to be published (Botha and Lotter, 1990a? Botha 
and Lotter, 1990b; Botha et al. 1987; Botha et al.
1986) .
In this study the compatibility of PL HC1 with various 
excipients is investigated by three different methods.
A comparison is made between the DSC compatibility 
screening technique, conventional "one factor at a time" - 
isothermal stress testing utilizing TLC and isothermal 
stress testing based on a Plackett-Burman factorial 
design. In contrast to Chrzanowski et al (1986) the more 
generally accepted qualitative approach to the 
interpretation of DSC thermograms is used. It should 
also be noted that although Plackett-Burman designs have 
been recommended for preformulation compatibility 
studies by several authors (Connors et al. 1986c; Motola 
and Agharkar, 1984), no recent applications of this
approach to compatibility testing or comments on its 
validity could be found in the primary literature.
5.3.2 METHODOLOGY
5.3.2.1 MATERIALS AND EQUIPMENT
PL HC1 (Fluka, Buchs) was used throughout. The following 
excipients were used: Eudragit RSPM (Rohm Pharma, 
Weiterstadt), ethyl cellulose 10 cps (Fluka, Buchs),
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methyl cellulose 25 cps (Fluka, Buchs), Avicel pH 101 
(FMC Corp, Philadelphia P.A.), anhydrous lactose 
(Sheffield Products, Norwhich N.Y.), Ludipress (BASF, 
Ludwigshafen), starch BP (Holpro Analytics, 
Johannesburg), mannitol (Riedel-de-Haen, Seelze), 
Aerosil 380 (Degussa, Frankfurt), magnesium stearate 
(Fluka, Buchs), stearic acid (Fluka, Buchs). DSC 
screening was performed in standard aluminium pans on a 
TA3000 system (Mettler, Greifensee) equipped with a DSC 
20 cell. For isothermal stress testing samples were 
stored in a thermostatically controlled oven (Memmert, 
Schwabach). Silica gel HF 60 chromatoplates (E Merck, 
Darmstadt) were used to detect decomposition in the 
conventional isothermal stress study. The Beckman System 
Gold liquid chromatograph (San Ramon, C.A) as previously 
described (section 5.2.2) was used to obtain the 
quantitative results required for the Plackett-Burman 
experimental design.
5.3.2.2 DSC SCREENING
PL HCl-excipient mixtures containing lubricants or 
glidants (ie magnesium stearate, stearic acid and 
Aerosil) were prepared in a 5:1 ratio. All other PL 
HCl-excipient mixtures were prepared in a 1:5 ratio. 
Samples of the mixtures and the individual substances 
(3-8 mg) were weighed into standard aluminium pans. 
Before sealing the lids were perforated to allow even 
distribution of nitrogen (see section 2.6.3). The 
samples were then heated at a rate of 7°C/min over a
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temperature range of 30-220°C in an atmosphere of flowing 
nitrogen. The thermograms were interpreted according to 
the guidelines of van Dooren (1983) and Smith (1982).
A classification of no incompatibility, possible 
incompatibility and probable incompatibility as proposed 
by Smith (1982) was used.
5.3.2.3 CONVENTIONAL ISOTHERMAL STRESS STUDY
The ratios for the PL HCl-excipient mixtures used in DSC 
screening were also used in this study. Each excipient 
mixture (approximately 60 mg) was prepared by blending - 
the components in glass vials with the aid of a 
vortexing device. The glass vials were then stored at 
40°C, 75% RH (see section 3.3.4.2.2) for 21 days.
Duplicate mixtures stored at 25°C, 11% RH were used as 
controls. A moderate temperature of 40°C was chosen to 
limit inherent PL HC1 decomposition. The solid state 
stability studies of PL HC1 on its own showed that PL 
HCl undergoes significant decomposition at 55°C. It is 
common to add water (up to 5%) directly to the powder 
mixtures and then to seal the vials before storage at 
elevated temperature (Carstensen, 1974; van Dooren 
1983). In this study the powder mixtures were exposed to 
moisture stress by storage at constant humidity. This 
takes into account factors such as powder mixing, 
particle size, surface area and moisture penetration 
(Ahlneck and Lundgren, 1985) and therefore represents a 
more realistic experimental situation. After three weeks 
the TLC procedure described in section 2.3 was used to
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test the various samples for decomposition products. The 
samples were also assessed visually.
5.3.2.4 ISOTHERMAL STRESS STUDY BASED ON A PLACKETT- 
BURMAN EXPERIMENTAL DESIGN
5.3.2.4.1 DERIVATION OF THE DESIGN
It was previously mentioned that the smallest Plackett- 
Burman design requires 8 trials. A general requirement 
for any two level Plackett-Burman design is that the sum 
of the trials (N) must be a multiple of 4, ie. designs *
can be derived for 8, 12, 16, 20, 24.... 100 trials.
For this study a 24 trial design was derived by 
following the procedure outlined by Plackett and Burman 
(1946). The procedure is described in detail in Appendix 
IVb. The design is shown in Table 5.2. In addition to 
the various excipients, the effect of temperature and 
relative humidity are also evaluated. The "+"and 
symbols indicate whether a variable was present at a low 
or high level in a specific trial. The high and low 
levels for the variables are summarized in Table 5.3.
Variables N to W are dummy variables and are used to 
calculate the experimental error inherent in the design 
(Plackett and Burman, 1946). In turn this is used to 
calculate the minimum significant variable effect (Em ) . 
The calculation of En3 and of the main effects is 
explained in Appendix IVb. Any main effect having an 
absolute value greater than EH3 is considered to be
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statistically significant on the stability of the drug
Table 5.2 Plackett-Burman design for study of 13 
variables in 24 trials
Variables Dummy variables
%RECTrial A B C D E F G H I J K L M N O P Q R S T U V w
1 + + + + + — + — + + — — + + — — + — + — — — — Y1
2 - + + + + + - + - + + - - + + - - + - + - - - Y2
3 - - + + + + + - + - + + - - + + - - + - + - - Y3
4 - - - + + + + + - + - + + - - + + - - + - + - Y 4
5 - - - - + + + + + - + - + + - - + + - - + - + Y5
6 + - - - - + + + + + - + - + + - - + + - - + - Y6
7 - + - - - - + + + + + - + - + + - - + + - - + Y7
8 + - + - - - - + + + + + - + - + + - - + + - - Y 8
9 - + - + - - - - + + + + + - + - + + - - + + - Y9
10 - - + - + - - - - + + + + + - + - + + - - + + Y10
11 + - - + - + - - - - + + + + + - + - + + - - + Yll
12 + + - - + - + - - - - + + + + + - + - + + - - Y12
13 - + + - - + - + - - - - + + + + + - + - + + - Y13
14 - - + + - - + - + - - - - + + + + + - + - + + Y14
15 + - - + + - - + - + - - - - + + + + + - + - + Y15
16 + + - - + + - - + - + - - - - + + + + + - + - Y16
17 - + + - - + + - - + - + - - - - + + + + + - + Y17
18 + - + + - - + + - - + - + - - - - + + + + + - Y18
19 - + - + + - - + + - - + - + - - - - + + + + + Y19
20 + - + - + + - - + + - - + - + - - - - + + + + Y20
21 + + - + - + + - - + + - - + - + - - - - + + + Y21
22 + + + - + - + + - - + + - - + - + - - - - + + Y22
23 + + + + - + - + + - - + + - - + - + - - - - + Y23
24 Y24
Sum + 
Sum - 
Effect
Key: A stearic acid; B magnesium stearate? C Aerosil 380;
D lactose; E Ludipress; F corn starch? G Avicel pHlOl;
H methylcellulose; I ethylcellulose; J Eudragit RSPM; K 
mannitol; L relative humidity; M temperature; N to W dummy 
variables; %REC percentage of drug recovered;
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Table 5.3 High ( + ) and low (-) levels for the 
variables used in the experiment
Variable 11 11 II _  II
A Stearic acid 2 mg 0 mg
B Magnesium stearate 2 mg 0 mg
C Aerosil 380 2 mg 0 mg
D Lactose 50 mg 0 mg
E Ludipress 5 0 mg 0 mg
F Corn starch 50 mg 0 mg
G Avicel pHlOl 50 mg 0 mg
H Methylcellulose 5 0 mg 0 mg
I Ethylcellulose 50 mg 0 mg
J Eudragit RSPM 5 0 mg 0 mg
K Mannitol 50 mg 0 mg
L Relative humidity 75% 11%
M Temperature 55°C 25°C
The use of 10 dummy variables in this study thus yields 
results with 10 degrees of freedom. Various authors have 
suggested that Plackett-Burman designs can be used to 
evaluate up to N-l factors with N trials (eg up to 11 
variables in 12 trials) (Connors et al. 1986; Nyqvist, 
1986). This is possible, but such designs do not 
incorporate any dummy variables. The significance of the 
measured main effects can therefore not be determined 
correctly. This greatly reduces the value of the 
experiment. The scientist therefore has to weigh up the 
need to obtain statistically sound and meaningful 
information against the additional work required to 
analyse a greater number of samples and the additional 
amount of drug consumed. For 13 variables it is good 
practice to have at least 7 degrees of freedom (ie. 20 
trials). In this case a 24 trial experiment (10 degrees 
of freedom) was selected.
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5.3.2.4.2 PREPARATION AND STORAGE OF POWDER MIXTURES
Twenty four powder mixtures were prepared by weighing 
the reguired amounts of excipient into glass vials in 
accordance with the 24 trial factorial design (Table 
5.2). Each mixture corresponds to one trial and only 
those excipients indicated as being present at a high 
level (+) for that particular trial were included. The 
amounts for each of the excipients have previously been 
given in Table 5.3. To each excipient combination 
approximately 10 mg PL HC1 (accurately weighed) was 
added. The powders were then blended in the glass vials 
with the aid of a vortexing device. Each mixture was 
stored in a dessicator containing the relevant salt 
solution (see section 3.3.4.2.2). The dessicators were 
then placed into ovens providing the required 
temperatures (Table 5.3). A storage time of 14 days was 
allowed.
5.3.2.4.3 ANALYTICAL PROCEDURE
After 14 days storage the powder mixtures were analysed 
to determine the remaining amounts of PL HC1. For this 
purpose the previously described HPLC method was used 
(section 2.4.2). Each sample was analysed three times.
5.3.3 RESULTS AND DISCUSSION
5.3.3.1 DSC SCREENING
The DSC traces of PL HC1, the excipients and their 
corresponding mixtures are shown in Figures 5.4-5.14
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The thermograms of the PL HC1 mixtures containing 
Eudragit RSPM, Avicel pHlOl, methylcellulose, 
ethylcellulose, Aerosil 380 and stearic acid (figures 
5.4-5.9) exhibit all the thermal features of the 
individual components. In general the broad melting 
endotherm of PL HC1 (ca. 178°C) appears even broader and 
shallower and occurs at a slightly lower temperature. 
However, this may be attributed to the mixing process, 
which lowers the purity of each component in the 
mixture, thus resulting in slightly broader and lower 
melting points (Smith, 1982). Slight variations in peak 
shape and melting point may also be caused by varying 
sample geometries (Giron-Forest, 1984). The 
characteristic broad endotherms between 40°C and 140°C 
observed for the celluloses can be attributed to the 
loss of residual water from these polymers (Botha and 
Lotter, 1990a). No incompatibility could therefore be 
detected for Eudragit RSPM, Avicel, methylcellulose, 
ethylcellulose, Aerosil, and stearic acid.
Figure 5.4 DSC thermograms of Eudragit RSPM, PL HCl and 
a PL HCl:Eudragit RSPM (1:5) mixture.
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Figure 5.5 DSC thermograms of Avicel pHlOl, PL HCl and 
a PL HCl:Avicel pHlOl (1:5) mixture.
50 100 150 200 250
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Figure 5.6 DSC thermograms of methylcellulose, PL HCl 
and a PL HCl:methylcellulose (1:5) mixture.
Figure 5.7 DSC thermograms of ethylcellulose, PL HCl 
and a PL HCl:ethylcellulose (1:5) mixture.
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Temperature "C
Figure 5.8 DSC thermograms of Aerosil 380, PL HCl and 
a PL HCl:Aerosil 380 (5:1) mixture.
Temperature °C
Figure 5.9 DSC thermograms of stearic acid, PL HCl and 
a PL HCl:stearic acid (5:1) mixture.
The DSC trace of magnesium stearate (figure 5.10) shows 
two shallow, broad endotherms in the region of 50°C to 
110°C. The lower endothermic peak corresponds to the 
melting point of magnesium stearate. The DSC trace of 
the PL HCl : magnesium stearate (5:1) mixture also 
shows several small endothermic peaks in this region. 
The peaks could not be directly correlated with those of 
pure magnesium stearate. However, the PL HCl peak 
remains largely unchanged. Incompatibilities involving 
magnesium stearate are frequently observed by DSC. 
However, these are often of a physical nature and due to
132
the low concentrations of magnesium stearate in the 
final dosage form and are often irrelevant (Gordon et 
al, 1984; Wells, 1988d).
Temperature °C
Figure 5.10 DSC thermograms for magnesium stearate, PL 
HCL and a PL HC1:magnesium stearate mixture.
Magnesium stearate is widely regarded as the lubricant 
of first choice and any implications for the stability 
of the formulation must be weighed up against the 
difficulties of finding a suitable substitute. Judging 
from the appearance of the DSC trace a significant 
solid-solid interaction is unlikely, but nonetheless 
possible.
Starch also exhibits a broad and shallow endotherm 
between 40°C and 120 °C (Figure 5.11). This may again be 
attributed to the loss of bound water. The DSC trace of 
the PL HC1 : starch (1:5) mixture shows several 
interesting features. The PL HC1 endotherm is broadened 
and peak temperature has been shifted upwards (185°C). 
An additional broad and shallow endotherm occurs at 
220°C. This may indicate an incompatibility. However, the 
additional endotherm occurs after the melting point of
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PL HC1 and is very close to the pyrrolytic decomposition 
temperature for PL HC1.
Temperature °C
Figure 5.11 Thermograms for starch, PL HC1 and a 
PL HCl:starch mixture
The observed interaction therefore involves a liquid 
phase and may also involve pyrrolytic degradation 
products. The evidence for a solid-solid incompatibility 
is therefore not conclusive. Nonetheless starch should 
be avoided until more information on its interaction 
with PL HCl can be obtained.
Mannitol exhibits a prominent sharp melting endotherm 
with a peak temperature of 168°C. This coincides with the 
onset of the PL HCl melting endotherm (Figure 5.12). The 
DSC trace of the PL HCl: mannitol mixture shows two 
large partially overlapping endothermic peaks. The peak 
temperatures occur at 145°C and 158°C respectively. Such 
large shifts in peak temperature are indicative of a 
strong interaction between the two components. 
Furthermore the second endotherm which probably 
corresponds to PL HCl is much larger and narrower when
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compared to pure PL HC1. Mannitol and PL HC1 are 
probably incompatible.
Temperature °C
Figure 5.12 DSC thermograms of mannitol, PL HC1 and a 
PL HCl:mannitol mixture (1:5).
An examination of Figures 5.13 and 5.14 reveals that 
lactose and Ludipress (which comprises lactose 
granulated with povidone and crospovidone) may also be 
incompatible with PL HCl.
Figure 5.13 DSC thermograms for lactose, PL HCl and a 
PL HCl:lactose mixture.
The thermograms of the PL HCl: lactose and PL 
HCl:Ludipress (1:5) mixtures show an additional
prominent endotherm in the region of 160°C to 170 °C.
In both cases the small exothermic peak occurring between
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the characteristic exotherms is obliterated.
mixture of PL HC1:Ludipress (1:5)
The results of the DSC compatibility screening can be 
summarized as follows:
No or unlikely incompatibility: Aerosil 380, Avicel 
pHlOl, ethylcellulose, Eudragit RSPM, magnesium stearate 
and stearic acid.
Possible incompatibility: corn starch.
Probable incompatibility: anhydrous lactose, Ludipress 
and mannitol.
It should be emphasized that the observed aberrations in 
the thermograms may be caused by physical rather than 
chemical interaction. Chemical incompatibility remains 
to be proven by stability testing.
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5.3.3.2 CONVENTIIONAL ISOTHERMAL STRESS TESTS
The PL HCl-excipient mixtures stored at 40°C, 75% RH
showed the following changes after 21 days:
Table 5.4 Visual assessment of PL HCl-excipient 
mixtures after 21 days storage at 40°C, 75% RH.
Excipient mixture Observation
PL HCl:mannitol (1:5) Extensive browning 
powder is lumpy and 
moist
PL HCL:Avicel pHlOl (1:5) No change,white and 
fine powder.
PL HCl:Eudragit RSPM (1:5) White, powder caking 
has occured
PL HCl:starch (1:5) White to slightly 
yellow
PL HCl:lactose (1:5) Yellow
PL HCL:Ludipress (1:5) Yellow, appears moist
PL HCl:methylcellulose (1:5) Slightly yellow
PL HCl:ethylcellulose (1:5) Slightly yellow
PL HCl:Aerosil 380 (5:1) Yellow
PL HC1:magnesium stearate (5:1) Slightly yellow
PL HCl:stearic acid (5:1) Slightly yellow
PL HCl Slightly yellow
In all cases the controls (stored at 25°C, 11% RH) 
showed no obvious change in appearance.
The results of the TLC analysis are shown in Figure 
5.15. Significant levels of decomposition products could 
be observed near the origin for PL HCl :mannitol, PL
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HCl:lactose and PL HC1:Ludipress samples. A smaller zone 
of decomposition products is also barely visible at the 
origin of the PL HCl:starch sample. It appears that the 
greatest decomposition was caused by mannitol. No 
differentiation could be made between the other 
excipients.
Figure 5.15 Chromatograms of the various PL HCL- 
excipient mixtures. Key: 1 PL HCl; 2 PL HCl:Avicel; 3 PL 
HCl:ethylcellulose; 4 methylcellulose; 5 PL HCl: 
mannitol; 6 PL HCl:starch; 7 PL HCl:Ludipress; 8 PL 
HCl:lactose; 9 PL HCl:Eudragit RSPM; 10 PL HCl: Aerosil 
380; 11 PL HCl; 12 PL HCl :Magnesium stearate; 13 PL 
HCl:stearic acid;
TLC analysis of the controls showed that no significant 
breakdown occurred when stored at 25°C, 11% RH
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for 3 weeks.
PL HC1 has been identified as a moisture sensitive drug, 
undergoing both physical and chemical changes at 
elevated levels of atmospheric moisture (sections 3.4 
and 5.1). Furthermore many drug-excipient interactions 
are moisture mediated. Mannitol was therefore selected 
as it is non hygroscopic and is often combined with 
moisture sensitive drugs (Peck et al. 1989; Handbook of 
Pharmaceutical Excipients, 1986a). In accelerated 
excipient compatibility tests on vitamins A, B1 and C it 
was found that mannitol was the excipient of choice due 
to its low moisture content (Wai et al. 1962).
Furthermore mannitol can be used for direct compression. 
This would be advantageous for PL HC1 as it is also 
known to react with aliphatic alcohols (Nurnberg, 
1961)(section 2.3.1) often used as non aqueous 
granulating fluids. The reaction of the PL hemiacetal 
ring with alcohols may also be the cause of the strong 
interaction with mannitol which is a hexahydric alcohol 
molecule. At the higher moisture and temperature levels 
hydrolysis of the PL hemiacetal may also occur (section 
5.1) resulting in the formation of the free aldehyde 
form of PL. The free carbonyl is highly reactive and may 
also react with the various mannitol hydroxy groups.
Lactose is a particularly useful diluent and filler as 
it is inexpensive, not excessively hygroscopic, has good 
compaction properties and is compatible with most drugs
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(Peck et al. 1989; Handbook of Pharmaceutical
Excipients, 1986b). However, lactose and Ludipress
(which is lactose based) appear to be of limited value
\
for any formulation containing PL HC1 as they chemically 
interact with the latter. Lactose is known to undergo a 
non enzymatic browning reaction (generally known as the 
Maillard reaction) with amines (Duvall et al. 1964). The 
first step in the Maillard reaction involves a 
condensation reaction between an amino group and the 
carbonyl group of a reducing sugar. The end products of 
the complex reaction sequence are the characteristic 
brown nitrogenous polymers known as melanoidins (Labuza 
and Saltmarch, 1981). The reaction is promoted by 
alkaline and humid conditions (Duvall, 1964). In their 
compatibility study of various amphetamines with lactose 
Duvall et al (1965) found that the Maillard reaction 
occurred only in primary amine derivatives. It appears 
that this concept has since been generally accepted. As 
PL HC1 has a tertiary amine group the Maillard reaction 
would therefore be ruled out as a possible mechanism for 
the interaction with lactose. However, in food systems 
vitamin B6 has been reported to take part in Maillard 
type reactions (Klaui, 1979). Furthermore in their 
review of the Maillard reaction Labuza and Saltmarch 
(1981) do not rule out reactions involving secondary and 
tertiary amines, they merely state that primary amines 
react most rapidly. The possibility of an interaction 
between the protonated pyridine nitrogen of PL HCl and 
free lactose carbonyl groups should therefore be
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considered. Alternatively, the reaction may again 
involve the unstable, reactive hemiacetal ring of PL and 
the free hydroxy groups of lactose. Such a reaction may 
also occur in the presence of / starch.
It can be concluded that at elevated temperature and 
humidity mannitol, lactose, Ludipress and to a lesser 
extent corn starch adversely affect the stability of PL 
HC1 . The results therefore correlate well with the 
probable incompatibilities detected by DSC screening. 
However, both methods are crude from a quantitative 
point of view and no conclusion could be reached on the 
extent of these negative interactions except that the 
reaction with mannitol appeared to be the most severe 
and starch seemed to react the least.
5.3.3.3 ISOTHERMAL STRESS TESTING USING A PLACKETT- 
BURMAN EXPERIMENTAL DESIGN
The full design showing % recovery of PL HC1 per trial 
is shown in Table 5.5 . % Recovery of PL HC1 was 
calculated from the mean of three HPLC determinations. 
To avoid sampling errors the whole sample was used. The 
relevant data can be found in Appendix IVc.
From the % recoveries the average effect was calculated 
for each variable as outlined in Appendix IVb. Using 
the dummy variables the standard deviation of the 
variable effect (sVE) was calculated to be 0.968. From 
this the minimum significant variable effects (Ems) were
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calculated at the 90% and 60% levels of confidence (see 
to Appendix IVb). Table 5.6 compares the average effects 
(main effects) of the variables with the at various 
levels of confidence. \
Table 5.5 Plackett-Burman design showing % PL HC1 
recovered per trial and the average effect of each 
variable
Variable Dummy variable
Trial A B C D E F G H I J K L M N O P Q R S T u V W %REC
1 + + 4- + + - + - 4- 4- — — + + — — + — 4- — — — - 95.15
2 - + + + + 4- - + - 4- + - - + 4- - - 4- - 4- - - - 93.91
3 - - + + + + + - + - + + - - + + - - 4- - 4- - - 97.14
4 - - - + 4- + + + - + - + 4- - - + + - - 4- - 4- - 80.32
5 - - - - + + + + + - 4- - + + - - + 4- - - 4- - 4- 92.33
6 + - - - - + + 4- 4- 4- - + - + + - - 4- 4- - - 4- - 97.03
7 - + - - - - + + + + + - + - 4- + - - 4- 4- - - 4- 93.60
8 4- - + - - - - + + + 4- + - 4- - + 4- - - 4- 4- - - 97.17
9 - + - 4- - - - - + 4- + 4- + - 4- - + 4- - - 4- 4- - 78.10
10 - - + - 4- - - - - + + + + 4- - + - 4- 4- - - 4- 4- 76.14
11 4- - - + - 4- - - - - 4- 4- 4- 4- 4- - + - 4- 4- - - 4- 68.28
12 4- 4- - - + - + - - - - 4- 4- 4- + + - 4- - 4- 4- - - 86.29
13 - + 4- - - 4- - + - - - - + + + + + - 4- - 4- 4- - 100.6
14 - - + 4- - - 4- - + - - - - + 4- + 4- 4- - 4- - 4- 4- 99.67
15 + - - + + - - + - + - - - - 4- + + 4- 4- - 4- - 4- 98.06
16 + 4- - - + 4- - - 4- - + - - - - + 4- 4- 4- 4- - + - 88.67
17 - 4- + - - 4- + - - + - + - - - - 4- 4- 4- 4- 4- - 4- 96.33
18 4- - 4- + - - + 4- - - + - + - - - - 4- 4- 4- 4- + - 96.33
19 - 4- - + 4- - - + 4- - - + - 4- - - - - 4- 4- 4- + 4- 100.3
20 + - + - 4- + - - + + - - + - + - - - - 4- 4- 4- 4- 93.07
21 + + - + - 4- 4- - - + 4- - - + - + - - - - 4- 4- 4- 96.47
22 + + + - + - + 4- - - + 4- - - + - 4- - - - - 4- 4- 9 5 . 10
23 + + + + - + - + + - - + 4- - - + - 4- - - - - 4- 87 . 18
24 9 8 . 40
Key: A stearic acid? B magnesium stearate; C Aerosil 380;
D lactose; E Ludipress? F corn starch; G Avicel pHlOl;
H methylcellulose; I ethylcellulose? J Eudragit RSPM; K 
mannitol; L relative humidity; M temperature; N to W dummy 
variables; %REC percentage of PL HC1 recovered;
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Table 5.6 Summary of the compatibility test using a 
Plackett-Burman factorial design.
Variable Average
Effect
Significant 
2P<0.1 
(Ems=l.754)
Significant 
2P<0.4 
(Ems=0.851)
Stearic acid -0.338 No No
magnesium stearate 0.743 No No
Aerosil 380 2.168 Yes Yes
Lactose -0.993 No Yes
Ludipress -0.529 No No
Starch -0.957 No Yes
Avicel pHlOl 1.909 Yes Yes
Methylcellulose 2.429 Yes Yes
Ethylcellulose 1.382 No Yes
Eudragit RSPM -0.625 No No
Mannitol -2.468 Yes Yes
Relative Humidity -3.620 Yes Yes
Temperature -4.618 Yes Yes
As would have been expected, relative humidity and 
temperature were found to be significant destabilizing 
factors. Their effects were larger than those of the 
excipients. Mannitol was the only excipient whose 
destabilizing effect was significant at the 90% level of 
confidence, thus confirming the findings of the previous 
two studies. Corn starch and lactose were also found to 
have relatively large destabilizing effects significant 
at the 60% level of confidence. Excipient compatibility 
studies are of a predictive and preventative nature. An 
excipient which is deemed to have a significant 
destabilizing effect at the 60% level of confidence 
represents a considerable risk to the stability of the 
final dosage form. Good stability characteristics are 
imperative. If possible such excipients should thus be 
avoided.
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It is notable that according to this study starch has a 
relatively large destabilizing effect. This correlates 
with the possible interaction observed by DSC screening 
(section 5.3.3.1). However, upon accelerated ageing only 
a small amount of decomposition could be observed by TLC 
(section 5.3.3.2). An important difference between the 
design of conventional isothermal stress experiments and 
the Plackett-Burman design is that in the latter each 
excipient is evaluated 12 times, in each case in the 
presence of different levels and combinations of all the 
other factors. The conventional isothermal stress study 
is based on the analysis of a single sample. The 
potential for experimental error is therefore greater. 
Geometric factors due to inadequate sample mixing may 
play a role. Furthermore, the destabilizing effect of 
starch could be promoted by the presence of other 
excipients. Such secondary effects can not be determined 
by the Plackett-Burman design.
A slight discrepancy was also observed for Ludipress. 
DSC screening and TLC analysis after accelerated ageing 
of a PL HC1:Ludipress (1:5) mixture provided strong 
evidence of a chemical interaction. Using the Plackett- 
Burman design a relatively small destabilizing effect 
was calculated. Apart from the above mentioned possible 
reasons for the apparent differences between the 
studies, the following should be considered: Ludipress 
consists of lactose granulated with povidone and 
crospovidone. These two excipients could excercise a
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protective effect on PL HC1. Crospovidone in particular 
is able to sorb large quantities of water, this may 
reduce the amount of water available for degradation 
(see discussion on celluloses below). Furthermore, the 
TLC analysis employed in the previous study is not 
quantitative and relies on visual estimation of the size 
and intensity of degradation zones and tails. This may 
account for the inability to correctly distinguish 
between the destabilizing effects of lactose, Ludipress 
and starch.
A relatively low destabilizing effect was also observed 
for Eudragit RSPM. The effect may largely be due to the 
alkalinity of the excipient (Handbook of Pharmaceutical 
Excipients, 1986c). Alkaline conditions have been 
identified as detrimental to the stability of PL HC1 
(section 5.1). Eudragit RSPM is unlikely to be used in 
the large proportions that were used in this study 
(Eudragit:PL HCl, 5:1) as it is used mainly for film 
coating and for inclusion in delayed release matrices. 
Therefore it is unlikely that Eudragit RSPM will cause 
stability problems.
The only other destabilizing effect observed was for 
stearic acid. However, the effect is small. Furthermore 
it is possible that the melting of stearic acid had an 
effect on the interaction with PL HCl. Various melting 
points have been reported for stearic acid: 59-64°C, 51- 
62.5°C and 63-69.2°C (Handbook of Pharmaceutical
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Excipients, 1986d). A certain amount of melting can 
therefore be expected at 55°C. As the interaction does 
not exclusively occur in the solid state, no conclusions 
should be made. However,again it is unlikely that 
stearic acid woulcl cause stability problems.
A common trend in this study are the relatively large 
positive effects observed for the cellulose derivatives 
ie. Avicel, methylcellulose and ethylcellulose. The 
effects of methylcellulose and Avicel are significant at 
the 90% level of confidence. These excipients 
(especially methylcellulose and Avicel) are relatively 
hygroscopic. Generally such excipients would be used 
with caution in conjunction with moisture sensitive 
drugs. However, it is known that ethylcellulose 
stabilizes ascorbic acid (Schmidt, 1982). Furthermore, 
in stability studies on acetyl salicylic acid in various 
cellulose mixtures it was demonstrated that a proportion 
of the water appears unavailable for degradation. It 
appears that this water becomes strongly bound to the 
free hydroxy groups in the amorphous regions of the 
cellulose (Ahlneck and Alderborn, 1988). It is possible 
that the celluloses tested in this experiment exercise 
a protective effect on PL HC1 in a similar way. A 
considerable proportion of the moisture may therefore be 
strongly bound and unavailable for degradation 
reactions. The existence of various thermodynamic states 
of water in biopolymers such as cellulose has been 
extensively documented (Zografi, 1988; Zografi and
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Kontny, 1986; Zografi et al. 1984;),although the 
rigidity of this concept has recently been challenged 
(Ahlneck and Zografi, 1990) (see also section 3.3.4.1). 
Nonetheless it appears that in this case a considerable 
proportion of the sorbed moisture is bound by the 
celluloses thus greatly reducing the molecular mobility 
in the system. Conseguently the potential for 
interaction between moisture and PL HC1 is reduced. The 
lower stabilizing effect cf ethylcellulose may be due to 
the lower hygroscopicity.
The strong stabilizing effect (significant at the 90% 
level of confidence) observed for Aerosil 380 (colloidal 
silicon dioxide) may also be attributed to its moisture 
scavenging role. Colloidal silicone dioxide can sorb 
large quantities of water (up to 18% at 78% RH) and can 
be used as a drying agent for hygroscopic materials 
(Handbook of Pharmaceutical Excipients, 1986e). 
Furthermore, Aerosil is acidic and may also exert a 
stabilizing effect by maintaining an acidic 
microenvironment. PL has been shown to be very stable at 
low pH (see section 5.1).
The moderate stabilizing effect of magnesium stearate 
(significant at the 50% level of confidence) was 
unexpected. A possible explanation could be that 
magnesium stearate provides a hydrophobic coat for the 
PL HC1 particles. Water soluble vitamins stabilized by 
coating with hydrophobic fatty acids and mono- and
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diglycerides are commercially available (Schmidt, 1982).
Based on this study it can be recommended that mannitol, 
lactose and Ludipress and starch should not be combined 
with PL HCl.The destabilizing effect of Ludipress 
appears to be relatively low. However Ludipress is best 
avoided as it is used in relatively large quantities as 
a filler/diluent and its main component, lactose, has a 
substantial destabilizing effect on PL HCl.
Stearic acid and Eudragit RSPM have relatively small 
negative effects and are unlikely to be used in large 
quantities in solid dosage forms. They could therefore 
be used if no alternatives were available. However there 
is no apparent need for stearic acid as magnesium 
stearate, which has superior lubricity, appears to be 
compatible with PL HCl.
Methylcellulose, ethylcellulose, Avicel pHlOl 
(microcrystalline cellulose), Aerosil 380 (colloidal 
silicone dioxide) and magnesium stearate are the 
excipients of first choice. They do not show any 
incompatibility with PL HCl and possibly have 
stabilizing effects.
The finding that the celluloses and colloidal silicone 
dioxide exert significant stabilizing effects on PL HCl 
deserves further investigation. This may provide new 
insights on simple ways to stabilize moisture sensitive
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drugs.
5.3.4 CONCLUSION
The ability to assign a statistical significance to the 
observations made and to identify both destabilizing and 
stabilizing factors makes the isothermal stress study 
based on the Plackett-Burman experimental design the 
compatibility testing method of choice. DSC screening 
and conventional isothermal stress testing coupled with 
TLC analysis also proved to be reliable indicators of 
major chemical incompatibilities. Their shortcomings are 
their inability to give good estimates of the extent and 
significance of the destabilizing effects and their 
inability to detect stabilizing effects. An additional 
disadvantage of DSC screening is the uncertainty of 
whether the observed interaction is chemically 
significant or not. Additional isothermal stress studies 
are usually required to confirm the results. This 
largely negates the advantages of DSC screening.
It appears that in excipient compatibility testing the 
emphasis is often mainly on the detection of 
incompatibilities. However, the benefits of also 
investigating the stabilizing effects of various 
excipients are obvious, especially when formulating 
inherently unstable drugs such as PL HCl. This aspect 
may become increasingly important with the increasing 
use of drugs of biological origin such as peptide drugs 
developed by rDNA technology. From this point of view
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isothermal stress testing based on a Plackett-Burman 
experimental design provides a superior method of 
excipient compatibility testing. DSC screening is 
suitable as a complementary method to isothermal stress 
studies and to gauge excipient compatibility during 
preliminary stages when no stability indicating method 
is available. In terms of excipient- drug interaction 
studies the most useful area of application for DSC 
would appear to be the study of pharmaceutically 
important physical interactions such as the formation of 
a solid dispersion of a poorly soluble drug in water 
soluble carrier materials (Ford and Francomb, 1985; 
Grant and Abougela, 1982).
An "ideal" preformulation excipient compatibility test 
which is rapid, consumes only small guantities of drug 
and provides accurate, reliable, guantitative data 
remains yet to be developed.
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CHAPTER SIX
6. CONCLUSION
The aim of this study was to generate the necessary data 
required for the design of a stable, safe and effective 
solid dosage form containing PL HC1. The research work 
was therefore concentrated in four areas: analytical 
preformulation, elucidation of solid state properties of 
PL HC1, solubility analysis and stability analysis.
As PL HCl has not been previously used in pharmaceutical 
products, only a few suitable analytical methods were 
available for this study. Consequently new UV 
spectrophotometric and HPLC methods suitable for the 
routine analysis of PL HCl in pharmaceutical samples and 
dosage forms were developed. Furthermore, it is believed 
that this dissertation contains the first thermal 
analytical profile of PL HCl.
A notable feature of the thermal investigations is the 
observation of polymorphic transitions in PL HCl. In 
subsequent moisture sorption studies it was demonstrated 
that polymorphic transitions could also occur when PL
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HCl was exposed to elevated levels of atmospheric 
moisture. This is significant for unstable and 
hygroscopic drugs such as PL HCl. Utilisation of the 
thermodynamically stable, less hygroscopic crystal form 
may provide a method whereby the destabilizing effect of 
moisture can be reduced.
The chemical stability studies further highlighted the 
critical importance of atmospheric moisture. By 
employing a Plackett-Burman experimental design it could 
be shown that moisture has a highly significant (90% 
level of confidence) destabilizing effect on PL HCl. The 
Plackett-Burman study also allowed the guantitative 
determination of the stabilizing and destabilizing 
effects of a series of common tableting excipients. 
Compared to excipient compatibility screens employing 
thermal analysis or conventional "one factor at a time" 
isothermal stress testing the factorial design was found 
to have two significant advantages: (1) Not only 
negative destabilizing interactions can be detected: 
positive stabilizing interactions can also be monitored. 
This aspect appears to have been previously disregarded 
by other workers. (2) The quantitative nature of the 
experiment allows excipients to be accurately graded in 
a hierarchy according to their stabilizing effects.
Due to the pragmatic and task orientated nature of 
preformulation studies, the results are usually 
presented in the form of a brief preformulation data
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sheet rather than in the form of an extended research
report. The most important findings are therefore 
summarized below.
6.1 PREFORMULATION DATA SHEET FOR PYRIDOXAL 
HYDROCHLORIDE
1. Name: Pyridoxal hydrochloride
2. Source and batch No.: Fluka Ag, Buchs, Switzerland
B/N 2912451089
3. Description: White, odourless, bitter/sour tasting
powder
4. Structural formula:
5. Empirical formula: C„H9N03. HC1
6. Molecular weight: 203.63
7. Solid phase compatibility and stability:
Compatible with: Most celluloses, Aerosil, 
magnesium stearate
Can be used if necessary: stearic acid, Eudragit 
RSPM
Incompatible with: Mannitol, starch, lactose, 
Ludipress
Possible degradation routes: Hydrolysis 
Degradation products: Rf 0.00,0.17,0.48 
Method of detection: Thin layer chromatography
O Hydrogen
H(9) H ( 1)
ci©
#  Carbon 
O Nitrogen 
O  Oxygen
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Adsorbent : Silica Gel 60HF 
Solvents : Chloroform:Methanol (75:25) 
Chamber : Unlined and unsaturated 
Detection : Short wave UV light
Effect of environmental factors: Extremely 
photolabile, thermolabile and sensitive to 
moisture, stable in acidic environment.
8. Solid state properties;
Melting point: 165°C-167°C with decomposition 
if not hermetically enclosed.
DSC thermogram indicates polymorphic transition 
occurring with melting.
Particle characteristics:
Particle shape and topography:
A mixture of large platy and tabular forms and 
smaller anhedral prismatic forms. Smooth 
surfaces with occasional fissures.
Particle size:
Mean 15.8 pm 
Range 3 - 60 pm
Hygroscopicity: (mg water/g after 14 days, 25° C)
at 11% RH = 1..93 , 54% RH = 3.73 ,
75% RH = 9.30 , 80% RH = 15., 78
PL HC1 is highly hygroscopic and deliquescent. 
Undergoes polymorphic transition to stable less 
hygroscopic form at RH 57% - 68%.
9. Solution data :
Solubility at 25°C (g/lOOml)
Water : 50 
Ethanol : 1.7
Propanol: sparingly soluble 
Acetone : slightly soluble
pH of 10% aqueous solution: 2
Partition coefficient: log P = -0.119
pka : pkx 4.2; pk2 8.66; pk3 13.0
10. Recommendation: PL HC1 is highly water soluble and 
no bioavailability problems are anticipated. 
Formulation of direct compression tablets or
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capsules is feasible. Stable solid dosage forms 
can be used provided suitable excipients are used 
(see 7). Care should be taken during manufacture 
and storage to limit exposure to moisture and 
light.
It is apparent that PL HC1 presents the pharmaceutical 
formulator with many challenging problems. This can be 
largely attributed to the chemical structure of PL HCl. 
The presence of the internal hemiacetal and its 
corresponding aldehyde functional group make PL HCl an 
inherently unstable and reactive drug molecule. A 
further contributing factor is the hygroscopicity of the 
compound. However, it is believed that the results of 
this study show that stable pharmaceutical products 
containing PL HCl can be formulated, thus providing the 
patient with benefits not available from current vitamin 
Bs products.
It is trusted that this work will contribute to the 
development and design of new solid dosage forms 
containing PL HCl.
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APPENDIX I
la) CALIBRATION DATA FOR UV SPECTROPHOTOMETRIC ASSAY
A calibration curve was constructed by measuring the 
absorbance of the 5 standard solutions given in the 
table below:
Standard Solution Concentration
(mg/1)
Absorbance
1 10.7 0.292
2 16.1 0.434
3 21.4 0.594
4 26.8 0.732
5 32.1 0.888
Least sguares linear regression provides the following 
eguation:
Absorbance = 0.0278 Concentration + 0.0085 
The regression coefficient, r, is 0.9997.
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The detection limit (DL) was determined from the 
measurement of 3 reagent blanks.
Ib) DETECTION LIMIT FOR UV SPECTROPHOTOMETRIC ASSAY
Reagent blank Absorbance
1 0.031
2 0.029
3 0.025
X 0.0283
S 0.0031
DL was calculated at the 99% level of confidence as
outlined by Cavenaghi et al (1978):
DL = 3______ s__________________
slope of calibration curve
ie DL = 3 x 0.0031 = 0.33 mg/1
0.0278
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Ic) SOLVENT STRENGTH PARAMETERS (E0) FOR MOBILE PHASE 
SOLVENTS IN HPLC AND TLC
Elutropic Solvent strength Solvent
series (E0)
1 0
2 0.01
3 0.04
4 0.18
5 0.29
6 0.38
7 0.40
8 0.42
9 0.45
10 0.49
11 0.56
12 0.56
13 0.58
14 0.62
15 0.63
16 0.65
17 0.82
18 0.88
19 0.95
20 high
21 high
n-Pentane
Hexane
Cyclohexane
Carbon tetrachloride
2-Chloropropane
Diethylether
Chloroform
Dichloromethane
Tetrahydrofuran
1,2-Dichloroethane
Acetone
1,4-Dioxane
Ethyl acetate
Dimethyl sulfoxide
Diethylamine
Acetonitrile
2-Propanol
Ethanol
Methanol
Acetic acid
Water
Solvent strengths (E0's) are additive. To calculate Ec 
for a combined solvent consisting of two or more 
components, eg Methanol: Acetonitrile (80:20), the 
proportional E0/s are calculated and added, 
i.e. E0 = 0.8 x 0.95 + 0.2 x 0.65 
E0 = 0.89
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Id) CALIBRATION DATA FOR HPLC ASSAY
Seven standard solutions of PL were prepared. Each of 
these was injected three times to determine the average 
ratio of the PL and PN peaks.
PL
Cone 
(mg/ml)
Ratio of Peak 
1 2
Areas
3
Mean
Area
X
Standard
Error
Sx
0.000100 0.000 0.000 0.000 0 0
0.000510 0.034995 0.033112 0.033882 0.03400 0.0005
0.001030 0.072815 0.075117 0.075598 0.07451 0.0008
0.005150 0.437893 0.440926 0.433386 0.4374 0.0022
0.010300 0.852225 0.877363 0.882008 0.8705 0.0093
0.051500 4.766038 4.892288 4.914985 4.8578 0.0803
0.103000 9.31375 9.475126 9.517522 9.435 0.0621
Regression analysis was performed using the System Gold 
(Beckman, San Ramon, CA) soft ware package. This yielded 
the following equation:
y = 0.010824 X  + 0.000241
where x is the ratio of the PL and PN peak areas and y 
refers to the PL concentration. A regression coefficient 
of r = 0.9995 was determined.
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APPENDIX II
Ila) DERIVATION OF MOISTURE SORPTION ISOTHERM 
At each humidity level three samples of PL HC1 were 
analysed for their water content. Details are given 
below:
Sample % MC RH Mean Standard
Error
95% Cl
1 0.1777 11.3% 0.1927 0.0123 0.1395-
2 0.2172 0.2459
3 0.1831 l
4 0.2773 21.6% 0.2716 0.0039 0.2547-
5 0.2641 0.2884
6 0.2734
7 0.2983 32.8% 0.2889 0.0065 0.2611-
8 0.2921 0.3169
9 0.2765
10 0.3769 54.4% 0.3736 0.0056 0.3495-
11 0.3812 0.3976
12 0.3627
13 0.3842 57.5% 0.3872 0.0058 0.3622-
14 0.3829 0.4121
15 0.3983
16 0.2341 68.6% 0.2447 0.0053 0.2218-
17 0.2508 0.2675
18 0.2491
19 0.9715 75.3% 0.9296 0.0269 0.8137-
20 0.8793 1.0455
21 0.9388
22 1.5473 80.9% 1.578 0.0249 1.4704-
23 1.5589 1.6852
24 1.627
25 52.033 97.3% 51.721 0.3630 50.159-
26 50.997 53.282
27 52.132
Key:
%MC = Percentage moisture content
RH = Relative humidity
95% Cl = 95% confidence interval
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APPENDIX III
Ilia) CALCULATION OF THE IONIC SPECIES OF PL IN SOLUTION
The following ionic equilibria exist for PL in solution 
(See section 4.3.2).
N eutra l form
-<-------- K , -------- ► ■ *------ K 2------- ► ■ *-------- K 3 --------- ►
(p K , = 4.21) (p K 2 = 8.68) (p K 3 =  13.0)
pKa = 4.94 
DKb = 4.30 
p K c  = 3.52 
p K d  = 3.2 
Kz = 0.54
From the above diagram it can be seen that the 
ionization constant for the dianion is 13.0. At pH 5.5 
and 7.4 its influence can therefore be assumed to be 
negligible.
CALCULATION OF THE PROPORTION OF PL IONS AT pH 5
The proportion of cation present can be calculated from
the Henderson-Hasselbach equation:
pH = pkt + loaf Remainder 1 
[Cation]
where: pkx = 4.21
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[Cation] = concentration of PL cation
[Remainder] = the concentration of remaining 
PL ions
thus: 5.5 = 4.21 + log [Remainder 1
[Cation]
therefore [Remainder] = 19.49 [Cation].... equation 1
Furthermore: [Cation] + [Remainder] = 1.... equation 2
Substituting equation 1 into equation 2:
[Cation] + 19.49 [Cation] = 1
20.498 [Cation] = 1
Thus the proportion of cationic species at pH 5.5 
is 4.87%.
/
THE PROPORTION OF ANIONS CAN NOW BE CALCULATED AS 
FOLLOWS:
[Anion] + [Remainder] = 0.9513.... equation 3
Substituting into the Henderson-Hasselbach equation, 
we have:
5.5 = 8.68 + loaf Anion 1____
[Remainder]
therefore [Anion] = 0.00066 [Remainder].... equation 4
Substituting equation 4 into equation 3, it can be 
seen that the proportion of the anionic species is 
0.06%.
THE PROPORTION OF NEUTRAL AND DIPOLAR FORMS CAN BE
CALCULATED WITH THE AID OF THE TAUTOMERIC CONSTANT Kz
ie kz = 0.64 = rDipolar 1
[Neutral]
thus 0.64 [Neutral] = [Dipolar].... equation 5
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Furthermore,
[Dipolar] + [Neutral] = 0.9506.... equation 6
Substiting equation 5 into equation 6, we have:
[Neutral] + 0.64 [Neutral] = 0.9506 
Therefore the proportion of the neutral PL species in 
solution at pH 5.5 is 57.96%. By subtraction the 
remaining dipolar species thus constitutes 37.1%. 
Similarly, it can be shown that at pH 7.4 the 
proportions of the ionic species are:
0.065% cations, 57.89% neutral, 37.1% dipolar and 
4.98% anion.
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APPENDIX IV
IVa) SOLID STATE STABILITY DATA FOR PL HC1
(see section 5.2.3)
Sample 1, Stored at 0% RH, 25°C
Original Mass 
11.0 mg
Amount found after two weeks
11.1 mg
11.1 mg 
10.9 mg
Mean 11.03 (100.3%) 
Standard Error 0.07
Sample 2, stored at ll% RH, 2 5°C
Original Mass 
10.4 mg
Amount found after two weeks
10.2 mg
10.3 mg 
10.2 mg
Mean 10.2 (98.4%) 
Standard Error 0.03
Sample 3, stored at 54% RH, 25°C
Original Mass 
10.5 mg
Amount found after two weeks 
10.4 mg
10.3 mg
10.3 mg
Mean 10.3 (98.4%) 
Standard Error 0.03
Sample 4, stored at 0% RH, 55°C
Original Mass 
10.0 mg
Amount found after two weeks 
9.8 mg
9.7 mg
9.8 mg
Mean 9.7 (97.6%) 
Standard Error 0.03
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S a m p l e  5, s t o r e d  a t  11% r h , 55°C
Original Mass 
11.3 mg
Amount found after two weeks
11.1 mg
10.8 mg 
10.7 mg
Mean 10.8 (96.17%)
Standard Error 0.120
Sample 6, stored at 54% RH, 55°C
Original Mass Amount found after two weeks
10.3 mg 9.8 mg
9.5 mg
10.2 mg
Mean 9.8 (95.47%)
Standard Error 0.203
Sample 7, stored at 54% RH, 55°C
Original Mass Amount found after two weeks
10.7 mg 7.3 mg
7.4 mg
7.4 mg
Mean 7.4 (69.2%)
Standard Error 0.033
Sample 8, stored at 54% RH, 55°C
Original Mass Amount found after two weeks
10.0 mg 9.1 mg
8.8 mg
8.9 mg
Mean 8.93 (89.33%)
Standard Error 0.088
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IVb) THE PLACKETT-BURMAN DESIGN
The method of Plackett and Burman (1946) provides 
saturated factorial designs that allow experiments to 
be carried out with a minimum of trials without 
compromising accuracy (the individual combinations 
tested within the multifactorial experiment are 
referred to as trials). Factors in the experiment are 
evaluated at 2 levels (ie a high (+) and a low (-) 
level). A constraint of the method is that the number 
of trials within a particular experiment has to be 
divisible by 4 for a 2 level factorial design. 
Furthermore the smallest design possible is an 8 trial 
experiment. The largest design that can be derived 
involves 100 trials, ie designs^for experiments N = 8, 
12, 16, 20, 24...100 can be derived.
Procedure for deriving a Plackett-Burman Design 
In their work Plackett and Burman (1944) have provided 
the first line for each factorial design from N = 8 to 
N = 100. In section 5.3 a design with 24 trials is
employed. For a Plackett-Burman design with N = 24 the 
first line can be represented as follows:
+ + + + + - + - + +
where "+" signifies the presence of a factor at a high 
level and signifies the presence of a factor at a
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l o w  le v e l .
Plackett-Burman designs are cyclical designs. The 
complete design is generated by cyclically shifting the 
first row by one place (N - 1) times and adding a final 
row of minus signs, thus
A B C D E F G H I J K L M N 0 P Q R S T U V w
1 + + + + + — + - + + — — + + — - + - + — — — -
2 - + + + + + - + - + + - - + + - - + - + - - -
3 - - + + + + + - + - + + - - + + - - + - + - -
4 - - - + + + + + - + - + + - - + + - - + - + -
5 - - - - + + + + + - + - + + - - 4- + - - + - +
6 + - - - - + + + + + - + - + + - - + + - - + -
7 - + - - - - + + + + + - + - + + - - + + - - +
8 + - + - - - - + + + + + - + - + + - - + + - -
9 - + - + - - - - + + + + + - + - + + - - + + -
10 - - + - + - - - - + + + + + - + - + + - - + +
11 + - - + - + - - - - + + + + + - + - + + - - +
12 + + - - + - + - - - - + + + + + - + - + + - -
13 - + + - - + - + - - - - + + + + + - + - + + -
14 - - + + - - + - + - - - - + + + + + - + - + +
15 + - - + + - - + - + - - - - + + + + + - + - +
16 + + - - + + - - + - + - - - - + + + + + - + -
17 - + + - - + + - - + + - - - - + + + + + - +
18 + - + + - - + + - - + - + - - - - + + + + + -
19 - + - + + - - + + - - + - + - - - - + + + + +
20 + - + - + + - - + + - - + - + - - - - + + + +
21 + + - + - + + - - + + - - + - + - - - - + + +
22 + + + - + - + + - - + + - - + - + - - - - + +
23 + + + + - + - + + - - + + - - + - + - - - - +
24
The rows of the design can then be taken as referring to 
trials (excipient mixtures) and the columns to variables 
affecting the formulation. In our case the experiment 
involves 11 excipients and 2 environmental factors 
(temperature and relative humidity). Only 13 columns 
therefore refer to assigned variables (real variables). 
Any 13 columns can be selected as the original 
variables. In this case the first 13 columns (A - M)
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were used. The remaining columns (N - X) are "dummy" 
variables. The designation of variables A - M and their 
high and low levels is shown in table 5.3 (section 
5.3.2.4.1) .
The complete design can therefore be depicted as 
follows:
Variable
Trial A B C D E F G H I J K L M N 0 P Q R S T U V w %REC
1 + + + + + — + — + + — — + + — — + - + — - — — Y1
2 - + + + + + - + - + + - - + + - - + - + - - - Y2
3 - - + + + + + - + - + + - - + + - - + - + - - Y3
4 - - - + + + + + - + - + + - - + + - - + - + - Y4
5 - - - - + + + + + - + - + + - - + + - - + - + Y5
6 + - - - - + + + + + - + - + + - - + + - - + - Y6
7 - + - - - - + + + + + - + - + + - - + + - - + Y7
8 + - + - - - - + + + + + - + - + + - - + + - - Y8
9 - + - + - - - - + + + + + - + - + + - - + + - Y9
10 - - + - + - - - - + + + + + - + - + + - - + + Y10
11 + - - + - + - - - - + + + + + - + - + + - - + Yll
12 + + - - + - + - - - - + + + + + - + - + + - - Y12
13 - + + - - + - + - - - - 4- + + + + - + - + + - Y13
14 - - + + - - + - + - - - - + + + + + - + - + + Y14
15 + - - + + - - + - + - - - - + + + + + - + - + Y15
16 + + - - + + - - + - + - - - - + + + + + - + - Y16
17 - + + - - + + - - + - + - - - - + + + + + - + Y17
18 + - + + - - + + - - + - + - - - - + + + + + - Y18
19 - + - + + - - + + - - + - + - - - - + + + + + Y19
20 + - + - + 7 + - - + + - - + - + - - - - + + + + Y20
21 + + - + - + + - - + + - - + - + - - - - + + + Y21
22 + + + - + - + + - - + + - - + - + - - - - + + Y22
23 + + + + - + - + + - - + + - - + - + - - - - + Y23
24 Y24
Sum + 
Sum - 
Effect
Key: A stearic acid; B magnesium stearate; C Aerosil 380;
D lactose; E Ludipress; F corn starch; G Avicel pHlOl;
H methylcellulose; I ethylcellulose; J Eudragit RSPM; K 
mannitol; L relative humidity; M temperature; N to W dummy 
variables; %REC percentage of drug recovered;
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ANALYSIS OF THE RESULTS
The main effect of each variable is calculated as 
follows: The "Y" values (% drug recovered) for each
variable where the variable is " + " are added and
recorded as "sum Similarly the "Y" values for each
variable where the variable is are added and
recorded as "sum — II •
The average effect of the variable on the response is
then calculated as follows:
Effect - fsum -H - (sum -1
N/2
for our particular study:
Effect = (sum +) - (sum -1
12
To calculate the significance of this effect, the 
standard deviation of the variable effect (sVE) is 
calculated from the dummy variables as follows: 
sVE = (Effect,,)2 + (Effect0)2. . . .+ (Effect,,)2 
number of dummy variables (ie 10) 
by referring to a statistical table for t values, the 
minimum significant variable effect (EM ) can be 
calculated as follows:
t • SVE
Any main effect having an absolute value greater than EM 
is considered to be statistically significant on the 
stability of the drug.
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IVc) ANALYTICAL RESULTS OBTAINED FOR THE PLACKETT-BURMAN 
EXCIPIENT COMPATIBILITY TEST
Trial Original Amount found after 
Amount of two weeks (mg)
Drug(mg)
Mean % 
Recovered
1 2 3
1 10.3 9.8 9.8 9.8 95..15
2 10.4 9.7 9.8 9.8 93.. 91
3 10.5 10.2 10.2 10.2 97..14
4 10.5 8.5 8.4 8.4 80., 32
5 10.0 9.2 9.2 9.3 92..33
6 10.1 9.8 9.8 9.8 97.,03
7 10.9 10.2 10.2 10.2 93 . 60
8 10.6 10.3 10.3 10.3 97., 17
9 10.2 8.0 7.9 8.0 78..10
10 10.2 7.8 7.7 7.8 76.. 14
11 10.3 7.0 7.0 7.1 68,. 28
12 10.7 9.1 9.6 9.0 86 ., 29
13 10.4 10.4 10.4 10.6 100,.64
14 10.1 10.1 10.0 10.1 99..67
15 10.3 10.1 9.9 10.3 98..06
16 10.0 8.9 8.8 8.9 88..67
17 10.0 9.7 9.6 9.6 96..33
18 10.0 9.9 9.5 9.5 96.,33
19 10.2 10.3 10.2 10.2 100.. 33
20 10.1 9.4 9.4 9.4 93 .07
21 10.4 10.0 10.1 10.0 96..47
22 10.2 9.5 9.9 9.7 95., 10
23 10.4 9.3 9.0 9.1 87..82
24 10.4 10.2 10.3 10.2 98 . 40
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CALCULATION OF EFFECTS
Variable effects were calculated using the following 
equation:
Effect = (sum Yi+) - (sum Y±-) *
24
Variable (sum Yi+) (sum Y±- ) Effect
Stearic acid 1098.8 1106.91 -0.338
Mag. stearate 1111.77 1093.94 0.743
Aerosil 1129.92 1077.88 2.168
Lactose 1090.94 1114.77 -0.993
Ludipress 1096.51 1109.2 -0.529
Corn starch 1091.37 1114.34 -0.957
Avicel 1125.76 1079.95 1.909
Methylcellulose 1132.0 1073.71 2.429
Ethylcellulose 1119.44 1086.27 1.382
Eudragit RSPM 1095.35 1110.36 0.625
Mannitol 1073.24 1132.47 2.468
Relative Humidity 1059.41 1146.3 -3.620
Temperature 1047.43 1158.28 -4.618
N 1103.41 1102.3 0.046
0 1100.89 1104.82 -0.164
P 1101.35 1104.36 -0.125
Q 1089.82 1115.89 -1.086
R 1090.04 1115.67 -1.068
S 1107.7 1098.01 0.404
T 1093.97 1111.74 -0.740
U 1132.26 1073.45 2.450
V 1101.87 1103.84 -0.082
w 1096.56 1109.15 -0.525
* for individual Yt values refer to table 5.5
(section 5.3.3.3 ) .
Using the formula for the standard deviation of the 
variable effect (sVE) a value of 0.967(6) was 
calculated for sVE Utilizing the appropriate student t 
values the minimum significant variable effects (E^) 
were then calculated:
For the 90% level of confidence E„g = 1.754
For the 60% level of confidence EHS = 0.851
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